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Summary
Background: Myocardial ischaemia causes necrosis and apoptosis of
myocytes, which cannot be replaced by division of surviving myocytes. The
search for effective therapeutic strategies for the prevention of myocardial
ischaemia is therefore an important goal. Clinical circumstances during which
myocardial ischaemia arise are represented by the acute phase of coronary
artery occlusion and also during cardiac bypass surgery. The main problem
with known modalities of cardiac protection is that they have to be employed
immediately before or during the acute ischaemie event, which is logistically
not possible in most cases.
The phenomenon of ischaemie preconditioning is a newly discovered
endogenous mechanism of myocardial protection. Ischaemie preconditioning
refers to the phenomenon whereby one or multiple short episodes of
ischaemia activates one or several endogenous mechanisms of protection
against myocardial ischaemia. Ischaemie preconditioning is associated with
two forms of cardioprotection : a classic form which provides immediate
protection and lasts up to 2 hours after the preconditioning ischaemia and a
delayed form (also called "second window of protection") which becomes
apparent 24 hours later and lasts for up to 3 days. The second window of
protection is not as powerful as the classic preconditioning phase, but confers
much longer protection. This form of myocardial protection is therefore
particularly interesting, as the ability to activate it could potentially provide a
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clinically useful method to protect against ischaemia without knowing when
the ischaemic event will occur.
It is not practically possible to use ischaemia to trigger preconditioning, and
therefore there has been interest in elucidating the signal transduction
pathways involved, in the hope of developing a pharmacological trigger of the
phenomenon. There are numerous non-ischaemie triggers of classic
preconditioning, that include beta-adrenergic stimulation, nitric oxide, opioids,
bradykinin and adenosine. Most non-ischaemic triggers of classic
preconditioning also seem to activate the second window of protection.
However, it is currently not known whether beta-adrenergic stimulation can
elicit a delayed cardioprotective response.
The mechanism of delayed cardioprotection involves both nitric oxide and
reactive oxygen species generation, as the protective effect is abolished by
inhibitors of nitric oxide generation as well as by agents that scavenge
reactive oxygen species. Beta-adrenergic stimulation with isoproterenol can
elicit classic preconditioning, and induces NO synthesis and generates
reactive oxygen species.
Aims:
To investigate whether beta-adrenergic preconditioning with isoproterenol
elicits delayed myocardial preconditioning
To determine whether the mechanism of beta-adrenergic cardioprotection
acts via nitric oxide and/or ROS generation.
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vMethods: Male Wistar rats (ca. 250 g) were used as experimental animals.
Isoproterenol was administered on Day 1, and 24 hours later the animals
were anaesthetized with a lethal dose of pentobarbital. Hearts were excised
and mounted on an aorta cannula of a Neely-Morgan perfusion system.
Regional ischaemia was induced by ligation of the left anterior descending
coronary artery for 35 minutes. The end-points used to assess myocardial
protection were both infarct size and functional recovery after 30 minutes of
reperfusion. The latter was assessed by perfusing the hearts in antegrade
fashion and determining haemodynamic parameters such as coronary flow,
aorta output, peak systolic pressure and calculated total external work. Infarct
size was determined using triphenyl tetrazolium staining and expressed as a
percentage of the region at risk, as determined by planimetry.
An isoproterenol dose response study was done by treating six groups of rats
intraperitoneally with different concentrations of isoproterenol and using
different administration protocols: Group 1(Control) received no treatment,
Group 2: 2 X 0.04 mg/kg; Group 3: 1 X 0.04mg/kg; Group 4: 2 X 0.02mg/kg;
Group 5: 4 X 0.004mg/kg; Group 6: 4 X 0.0004 mg/kg. Where isoproterenol
was administered repeatedly, the interval between administrations was one
hour.
To investigate the role of NO in delayed preconditioning, the non-selective NO
synthase antagonist NOJ-nitro-L-argininewas administered intraperitoneally an
hour before preconditioning with isoproterenol 4 X 0.0004mg/kg. The role of
the generation of radical oxygen species in isoproterenol induced
preconditioning was assessed by administration of the free radical scavengers
Stellenbosch University http://scholar.sun.ac.za
VI
Melatonin(5mg/kg), Mercaptopropionylglycine (1 mg/kg) and N-Acetylcysteine
(10 mg/kg). These agents were administered 5 minutes before
preconditioning with isoproterenoI4XO.0004mg/kg.
Due to the observation that melatonin was a very effective cardioprotective
agent, a sub-study was done to investigate its ability to protect the
myocardium if administered orally in drinking water for 7 days. The duration of
protection against ischaemia of orally administered melatonin was studied by
assessing the effect of withdrawal of oral (40 J..Lg/ml)melatonin for 2, 4 and 6
days. Serum levels of melatonin were measured to assess the relationship
between protection against infarction and levels of the drug in the circulation.
The conditions selected to measure serum levels were a control group (no
pretreatment), 2.5 and 5 mg/kg melatonin intraperitoneal groups and 4, 6 day
melatonin withdrawal groups.
Results: Isoproterenol induced delayed preconditioning against infarction was
successfully demonstrated. Delayed preconditioning was elicited with
increasing effectiveness by decreasing the dose and repeating intraperitoneal
administrations. The optimal dose and protocol of isoproterenol administration
was 4 X 0.0004mg/kg - hearts treated in this fashion had an infarct size of
11.3±1.7%, which was significantly smaller than that of control rats
(38.9±2.0%).
Following this, the mechanism of isoproterenol induced delayed
preconditioning was studied.
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Administration of NOl-nitro-L-arginine(17.5 mg/kg) intraperitoneally an hour
before preconditioning with isoproterenol (4XO.0004mg/kg), abolished the
protective effect of isoproterenol - infarct size was 36.4±3.9%, which was
similar to that of the control group (38.9±2.0%). Next, the role of the
generation of radical oxygen species in isoproterenol induced delayed
preconditioning was studied. When N-Acetylcysteine (10 mg/kg) was
administered 5 minutes before preconditioning with optimal isoproterenol
dose, cardioprotection was abrogated. Melatonin (5 mg/kg) and
Mercaptopropionylglycine (1 mg/kg) both had marked drug effects - control
animals treated with the radical oxygen species scavengers alone had similar
degrees of protection against infarction as animals preconditioned with
isoproterenol. Interestingly, melatonin pre-treatment also resulted in superior
functional recovery, apart from its protection against infarct size. Due to this
drug effect, both these drugs were not of use to assess the role of ROS in
isoproterenol induced delayed preconditioning.
The observation that melatonin was extremely effective to protect against
ischaemia 24 hours after its intraperitoneal administration resulted in a sub-
study which investigated the ability of orally administered melatonin to protect
against myocardial ischaemia. Two different doses of melatonin in the
drinking water were studied (20 and 40 Ilg/ml). The latter concentration
proved to be equally as effective against infarct size as intraperitoneal
administration of melatonin. Furthermore, withdrawal of melatonin for 2,4 and
6 days resulted in loss of the protective effect of melatonin after 2 days.
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Conclusions:
1. Beta-adrenergic stimulation with isoproterenol elicits delayed
myocardial preconditioning, and the optimal condition and dose of
administration is 4XO.0004mg/kg administered at one hourly intervals.
2. The mechanism of beta-adrenergic delayed preconditioning involves
the synthesis of both nitric oxide and reactive oxygen species.
3. Melatonin administered intraperitoneally as well as orally provides
potent protection against myocardial ischaemia, and results in both a
decrease in infarct size and improved functional recovery.
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Opsomming
Agtergrond: Miokardiale isgemie veroorsaak nekrose en apoptose van
miosiete wat nie deur verdeling van die oorblywende miosiete vervang kan
word nie. Die soeke na effektiewe terapeutiese strategieë wat lei tot die
voorkoming van miokardiale isgemie is dus "n belangrike doelwit. Kliniese
omstandighede waartydens miokardiale isgemie ontstaan, word deur die
akute fase van koronêre okklusie asook tydens hartomleiding chirurgie
verteenwoordig. Die hoof probleem met bekende modaliteite van kardiale
beskerming is dat dit toegedien moet word gedurende "n akute isgemiese
voorval, wat in meeste gevalle nie logisties moontlik is nie.
Die verskynsel van isgemiese prekondisionering is "n nuut ondekte endogene
meganisme van miokardiale beskerming. Isgemiese prekondisionering verwys
na die fenomeen waarbyeen of meer kort episodes van isgemie "n endogene
beskermingmeganisme teen miokardiale isgemie aktiveer. Isgemiese
prekondisionering word gekenmerk deur twee vorme van kardiale
beskerming:' n klassieke vorm wat onmiddellike beskerming bied en minstens
2 uur duur en "n vertraagde vorm ("tweede venster van beskerming") wat 24
uur later ontstaan en tot 3 dae kan duur. Die tweede venster van beskerming
is nie so kragtig soos die klassieke fase nie, maar bied langer beskerming.
Hierdie vorm van miokardiale beskerming is juis interessant want die vermoë
om dit te ontlok, bied juis "n kliniese relevante metode vir beskerming teen
isgemie, sonder om kennis te dra van wanneer die isgemiese gebeurtenis
gaan geskied.
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xDit is nie prakties moontlik om prekondisionering met behulp van isgemie te
ontlok nie en dus het daar belangstelling onstaan om die seintransduksie
paaie wat betrokke is, te ontrafel met die hoop om 'n farmakologiese sneller
van die verskynsel te ontwikkel. Daar is verskeie nie-isgemiese snellers van
prekondisionering, soos byvoorbeeld beta-adrenergiese stimulasie, stikstof
oksied, opioïede, bradikinien en adenosien. Die meeste nie-isgemiese
snellers van klassieke prekondisionering blyk om die tweede venster van
beskerming te aktiveer. Dit is huidiglik nie bekend of beta adrenergiese
stimulasie vertraagde prekondisionering kan ontlok nie.
Die meganisme van vertraagde miokardiale beskerming sluit in vorming van
beide stikstof oksied en vrye radikaal spesies, aangesien die beskermende
effek deur inhibitore van stikstof oksied sowel as deur vry radikaalopruimers,
opgehef word. Beta adrenergiese stimulasie met isoproterenol kan klassieke
prekondisionering ontlok en induseer NO sintese en genereer suurstof
radikaal spesies.
Doel:
Om te bepaal of beta-adrenergiese prekondisionering met isoproterenol
vertraagde miokardiale prekondisionering kan ontlok
Om te bepaal of die meganisme van beta-adrenergiese miokardiale
beskerming deur vorming van stikstof oksied en vry radikaal spesies
plaasvind.
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Metodes: Manlike Wistar rotte (250g) is as eksperimentele diere gebruik.
Isoproterenol is toegedien op Dag 1, en 24 uur later is diere verdoof met 'n
noodlottige dosis van pentobarbital. Harte is verwyder en gemonteer op die
aorta kannule van die Neely-Morgan perfusie sisteem. Streeksisgemie is deur
afbinding van die linker anterior dalende koronêre arterie vir 35 minute
teweeggebring. Die eindpunte gebruik vir die bepaling van miokardiale
beskerming was infarktgrootte en funksionele herstel na 30 minute van
herperfusie. Die laasgenoemde is bepaal deur harte volgens die werkhart te
perfuseer met bepaling van hemodinamiese parameters soos koronêre vloei,
aorta uitset, piek sistoliese druk en berekende totale eksterne werk. Infark-
grootte is bepaal deur gebruik van trifeniel tetrazolium kleuring en uitgedruk
as 'n persentasie van risiko area, bepaal deur planimetrie.
'n Isoproterenol dosis respons studie is gedoen deur gebruik van verskillende
konsentrasies van isoproterenol (intraperitoneaal toegedien) en gebruik van
verskillende protokolle: Groep 1 (kontrole) geen behandeling, Groep 2:2 X
0.04mg/kg; Groep 3:1 X 0.04mg/kg; Groep 4:2 X 0.02mg/kg; Groep 5:4 X
0.004mg/kg; Groep 6: 4 X 0.0004mg/kg. Waar isoproterenol herhaaldelik
toegedien was, is die interval tussen toedienings een uur. Die rol van stikstof
oksied in vertraagde prekondisionering is ondersoek deur die nie-selektiewe
stikstof oksied antagonis NOl-nitro-L-arginien intraperitoneaal, 'n uur voor
prekondisionering met isoproterenol (4xO.0004mg/kg) toe te dien. Die rol van
generasie van vry radikale in isoproterenol geïnduseerde prekondisionering is
ondersoek deur toediening van die vrye radikaalopruimers Melatonin
(5mg/kg), Merkaptopropionielglisien (1 mg/kg) and N-Asetielsisteïen
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(10mg/kg) Hierdie middels is 5 minute voor prekondisionering met
isoproterenol (4xO.0004mg/kg) toegedien.
As gevolg van die waarneming dat melatonien die hart baie effektief teen
isgemie beskerm het, is In substudie gedoen om die beskermingsvermoë van
orale melatonin te ondersoek. Die duur van beskerming teen isgemie van
oraal toegediende melatonin is na 2, 4 en 6 dae van onttrekking ondersoek.
Serum melatonien vlakke is gemeet om die verhouding tussen beskerming
teen infarksie en vlakke van middel sirkulasie te bepaal. Die toestande wat
geselekteer is om serum vlakke te meet, sluit in In kontrole groep, melatonien
2.5 en 5 mg/kg intraperitoneaal groep en 4,6 dae melatonin ontrekkingsgroep
Resultate: Vetraagde isoproterenol geïnduseerde prekondisionering teen
infarkgrootte is suksesvol gedemonstreer. Vertraagde prekondisionering is
meer effektief deur kleiner dosisse en herhaalde intraperitoneale toedienings
ontlok. Die optimale dosis en protokol van isoproterenol administrasie was 4x
O.0004mg/kg-harte wat op hierdie wyse behandel is, se infarktgrootte was
11.3±1.7%, wat beduidend kleiner was as die van kontrole rotte
(38.9±2.0% )(p<O.05).
Vervolgens is die meganisme van isoproterenol geïnduseerde vertraagde
prekondisionering ondersoek. Intraperitoneale toediening van Nffi-nitro-L-
arginien (17.5mg/kg) een uur voor prekondisionering met isoproterenol
(4xO.0004mg/kg), hef die beskermende effek van isoproterenol totaal op-
infarktgrootte was 36.4±3.9% wat gelyk was aan die van die kontrole groep
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(38.9±2.0%). Die rol van generasie van vry radikaal spesies in isoproterenol
geïnduseerde vertraagde prekondisionering is ondersoek deur toediening van
(10mg/kg) 5 minute voor prekondisionering. Voorafbehandeling met N-
Asetielsisteïen het isoproterenol-geïnduseerde beskerming opgehef.
Melatonin(5mg/kg} en Merkaptopropionielglisien (1 mg/kg) het egter beide
beduidende middel effekte gehad - kontrole diere behandel met suurstof
radikaal spesie opruimers alleen het soortgelyke beskerming teen infarksie as
geprekondisioneerde diere met isoproterenol getoon. As gevolg van hierdie
middeleffekte kon melatonien sowel as merkaptopropionielglisien nie gebruik
word om die rol van vry radikaalvorming te evalueer nie Melatonien
behandeling het tot beide In verhoogde funksionele herstel, sowel as In
afname in infarktgrootte gelei. In die substudie waar die vermoë van orale
melatonin toediening om die harte teen isgemie te beskerm is twee
verskillende dosisse van melatonin in die drinkwater bestudeer (20 en
40f.lg/ml). Laasgenoemde konsentrasie is bewys om hart net so effektief te
beskerm teen infarksiegrootte soos intraperitoneale toediening van melatonin.
Verder het ontrekking van melatonin vir meer as twee dae die verlies van
beskerming tot gevolg gehad.
Opsommend:
1. Beta-adrenergiese stimulasie met isoproterenol ontlok vertraagde
miokardiale prekondisionering die optimale protokol was
4xO.0004mg/kg toegedien elke uur.
2. Die meganisme van beta-adrenegiese vertraagde prekondisionering sluit
in generasie van beide stikstof oksied en vry radikaal spesies.
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3. Melatonien toediening, beide intraperitoneaal en oraal, bied kragtige
beskerming teen miokardiale isgemie gekenmerk deur 'n vermindering
in infarktgrootte en verbeterde meganiese herstel.
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CHAPTER 1
Introduction
Acute coronary occlusion is the leading cause of morbidity and mortality in the
Western world and according to the World Health Organization will be the major
cause of death in the world by the year 2020 (Murray & Lopes 1997). Thus, in the
United States and other economically developed countries of the world,
cardiovascular disease is reported to be the major cause of disability and mortality
(Bazzano et al., 2003). The four leading clinical syndromes of ischaemie heart
disease are angina pectoris, acute myocardial infarction, chronic post ischaemie
cardiac failure and sudden ischaemie death. Ischaemia due to atherosclerotic plaque
rupture or vasospasm of sufficient duration results in severe damage to the
myocardium which causes cellular injury and eventually cell death due to apoptosis
and/or necrosis. Acute myocardial ischaemia also has two other important
consequences: failure of contraction and arrhythmias.
Current strategies to combat the deleterious consequences of ischaemie injury
include anti-arrhythmic drugs, anti-thrombotic agents, organic nitrates (nitroglycine),
beta-receptor antagonists and calcium antagonists. These treatments generally
alleviate, but do not prevent ischaemie damage. An endogenous protective
mechanism against ischaemia does exist in the myocardium. This mechanism
enables the myocardium to adapt to transient ischaemie stress by changing its
phenotype in a manner that makes it resistant to ischaemie injury. This powerful
endogenous intracellular defence mechanism is known as ischaemie preconditioning.
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2Ischaemic preconditioning is a phenomenon whereby short periods of ischaemia and
reperfusion induce protection of the heart from the deleterious consequences of
subsequent prolonged ischaemia (Murray et el., 1986). Two types of preconditioning
have been recognized - classic preconditioning and delayed preconditioning (also
called "second window of protection"). Classic preconditioning provides immediate
cellular protection for one hour of duration (Downey et et., 1997a) but protection
disappears altogether 2h after the preconditioning ischaemia (Van Winkle et aI.,
1991). Ischaemie preconditioning protects myocytes against ischaemic cell death
(Murry et aI., 1986), and arrhythmias (Shiki & Hearse, 1987). Following this early
phase of protection a late (or delayed) phase that becomes apparent 12 to 24 hours
later, which lasts 3 to 4 days (Kuzuya et aI., 1993, Marber et aI., 1993). This late
phase of cardioprotection is called delayed preconditioning or "second window of
protection" (abbreviated "SWOP").
Classic preconditioning represents an adaptive response to potentially noxious
stimuli and involves activation of endogenous defence mechanisms. Although much
is known about the cellular basis of this adaptation, there are still large gaps in our
knowledge. Different plausible hypotheses have been proposed and several
mechanisms seem to be involved. Cell surface receptors, mitochondrial KATP
channels, free radicals, and protein kinase C all playa pivotal role in the signalling of
protection.
Due to its potential clinical importance, the second window of protection has
generated considerable interest. If the mechanism of this adaptive response can be
elucidated, it could be possible to exploit it pharmacologically to develop pre-emptive
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3strategies to protect the myocardium against situations where ischaemia arise.
Clinical examples of this are patients at risk of having a myocardial infarction and
patients undergoing to bypass surgery.
Both classic and delayed preconditioning can be elicited by interventions other than
brief ischaemia, such as pharmacological manipulations with nitric oxide donors
(Takano et aI., 1998), opioids receptor agonists (Fryer et aI., 1999), adenosine
receptor agonists (Baxter et aI., 1994), endotoxin (Brown et aI., 1990), rapid cardiac
pacing (Kaszala et aI., 1996), exercise (Yamashita et aI., 1999) and heat stress
(Currie et aI., 1988). Beta-adrenergic stimulation can also elicit classic
preconditioning (Lochner et aI., 1999, Nasa et aI., 1997), but it is currently not known
whether it elicits delayed preconditioning.
Over the past 15 years, it has been attempted to elucidate mechanisms of both early
and late ischaemie preconditioning (Cohen et aI., 2000, Bolli R, 2000). The aim was
to develop pharmacological agents that stimulate second messenger pathways
thought to be involved in preconditioning (but without causing ischaemia), in order to
develop novel approaches to prevent ischaemic damage of the myocardium.
In view of this, it was our aim to:
(i) investigate whether beta-adrenergic stimulation elicits delayed preconditioning
(li) elucidate the mechanism thereof.
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41.1 Classicpreconditioning
1.1.1 Triggersof preconditioningwith ischaemia
A trigger of preconditioning is considered to be a substance released
during ischaemia and/or during reperfusion that stimulates signalling
pathways in the myocyte and cause cellular changes that allow myocytes
to survive a prolonged episode of subsequent ischaemia. Downey et al.
(1997b) first demonstrated that the protection of ischaemie PC was
receptor mediated. Adenosine is a breakdown product of ATP and occurs
in high concentrations in ischaemie tissue (Van Wylen et aI., 1990).
Evidence supporting the role of adenosine as a trigger of classic
preconditioning came from Liu et aI., 1991 who showed that adenosine
receptor blockade with 8-(p-sulphophenyl)-theophylline (8-SPT) abolished
the infarct - limiting effect of preconditioning in rabbit heart (this was
confirmed by Cohen et aI., 1994). It was subsequently shown that transient
adenosine A1 receptor (but not A2 receptor) activation with selective
agonists reproduced the infarct - limiting effect of ischaemie
preconditioning in the rabbit, rat and dog (Liu et aI., 1991, Thornton et aI.,
1992, Tsuchida et aI., 1992, Auchampach et aI., 1993). A 5 min infusion of
adenosine or A1 receptor agonist N-6 (phenyl-2R-isopropyl) adenosine
was as effective as 5 min of ischaemia in protecting against infarct size
(Cohen et aI., 1994). Pharmacological evidence also supports a role for
adenosine A3 receptor activation in classic ischaemie preconditioning (Liu
et aI., 1994, Armstrong & Ganote, 1994, Armstrong & Ganote, 1995).
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5The adenosine A1 receptor also seems to be involved in delayed PC
(Baxter et aI., 1994). In a study in which non-preconditioned rabbits
received a single intravenous bolus of the highly selective adenosine1
receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) or saline
vehicle 24 hours prior to index coronary artery occlusion, increasing doses
of CCPA in the range 25-100 )-lg/kg resulted in progressive reduction in
infarct size compared to the saline treated animals, with maximum
protection observed at a dose of 100 )-lg/kg. CCPA has a 1DODO-fold
selectivity for the A1 versus A2 receptor and a subnanomolar affinity. A
subsequent study confirmed that this delayed action of A1 receptor
activation was mediated in the myocardium and not via peripheal actions
of adenosine, as late protection against ischaemia - reperfusion injury was
also evident in the isolated Langendorff-perfused rabbit hearts (Baxter et
al., 1997).
Results from experiments in which various receptor agonists and
antagonists were used suggest that several others triggers are involved,
including: bradykinin (Wall et aI., 1996), catecholamines (Bankwala et aI.,
1998), free radicals (Baines et aI., 1997), angiotensin" (Noda et aI., 1993)
nitric oxide (Vegh et aI., 1993) and opiates (Schultz et aI., 1997).
All these agonists are produced during ischaemia in the myocardium of
experimental animals and are therefore likely to playa role in initiating the
protective effects. It seems possible that these breakdown products are
released from the ischaemie myocardium, and act in a paracrine fashion to
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6activate protective cascades. In the rat adrenergic and opioid signalling
seem dominant, whilst adenosine and bradykinin signalling are more
important in rabbit myocardium (Edwards et aI., 2000).
1.1.2 Adrenergic receptors and classic preconditioning
Activation of the adrenergic receptors has been proposed to playa role in
ischaemie preconditioning. The possibility that catecholamine release was
an important trigger for preconditioning was entertained early. Adrenergic
receptors can be divided into three major groups, U1, U2 and [3-
adrenoceptors. The U1 group can be sub-divided into four subtypes - U1a ,
U1b , U1c and U1d respectively. Banerjee et al (1993) investigated the role
of the u1-adrenergic receptor in preconditioning. They reported that
norepinephrine induced preconditioning was blocked by an u-1 adrenergic
receptor antagonist. Nonselective U1 agonism with phenylephrine
protected rabbit myocardium from subsequent ischaemic injury (Tsuchida
et aI., 1994). This protection could be blocked by chloroethylclonidine, a
selective U1bantagonist, whereas methoxamine, an u1a-selective agonist,
failed to protect in this model. These results suggested that activation of
U1breceptors alone caused cardioprotection, or that full U1agonism was
required to exert protection. In a canine model of myocardial infarction,
however, methoxamine limited infarct size to a similar degree to that
obtained with ischaemic preconditioning (Kitikaze et aI., 1994). The dose
employed in this particular study, however, may have been sufficiently
high to allow methoxamine to act as a less selective agonist. Both
preconditioning with ischaemia and pre-treatment with methoxamine
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inhibited by a, f3-methyleneadenosine 5-diphosphate, but a, 13-
methyleneadenosine 5-diphosphate, which inhibits the protection afforded
by methoxamine, does not attenuate the cardioprotective effects afforded
by ischaemie preconditioning. Thus, the mechanism through which
cardioprotection is achieved appears to be different for methoxamine and
ischaemia.
1.1.3 Beta-adrenergic PC as a trigger of classic PC
Asimakis et al (1994) showed that beta-adrenergic receptor activation
could elicit cardioprotection, using functional recovery as endpoint.
However, it should be noted that in these experiments, the beta-blocker
propranolol did not abolish the protective effect of ischaemie
preconditioning.
A study by Nasa et al. (1997) investigated whether adrenergic stimulation
mimicked preconditioning cardioprotection. In this study rat hearts were
perfused for 2 minutes with either norepinephrine, phenylephrine or
isoproterenol followed by a 10 minute drug free perfusion. Pre-perfusion
with norepinephrine (0.25 f-lM) or isoproterenol (0.25 f-lM), but not
phenylephrine (10 f-lM) resulted in a better recovery of left ventricular
developed pressure in the post-ischaemie reperfused heart. Both the
norepinephrine and isoproterenol pretreated groups had a reduction in
creatine kinase release (measure of myocardial damage) and a similar
improvement of post-ischaemie cardiac contractile dysfunction as the
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reperfusion (i.e. ischaemie preconditioning) before prolonged ischaemia.
Pretreatment of hearts with timolol, a beta-blocker, abolished the
protective effects of norepinephrine, whereas pretreatment with
bunazosun, an «--t adrenoceptor blocker, did not affect the protective
effects of isoproterenol. These results suggested that brief stimulation of
cardiac beta-adrenoceptors were responsible for the preconditioning -
mimetic protective effect against post-ischaemie contractile dysfunction in
perfused rat hearts.
Lochner et al (1999) showed that beta-adrenergic blockade with alprenolol
bracketing one ischaemie episode of 5 minutes to trigger ischaemie
preconditioning, partially abrogated the protective effect - indicating a role
for the beta-adrenergic receptor in ischaemie preconditioning.
Furthermore, 5 minutes of transient beta-adrenergic stimulation with
isoproterenol at a dose of 10-7 M elicits classic preconditioning. The
mechanism through which beta- receptor stimulation protects seems to be
via the activation of p38 MAP kinase. Evidence for this is provided by
observation in our laboratory that bracketing of either a single episode (1 x
5 min) ischaemie preconditioning or isoproterenol-induced
pharmacological preconditioning by the p38 MAP kinase inhibitor SB
203580, abolished cardioprotection (Marais et al., 2001). In these
experiments, functional recovery was significantly reduced in both SB
203580 pretreated groups - cardiac output was reduced to 15.7±1.6 and
18.9±0.3 ml/min for single episode (1 x 5min) ischaemie preconditioning
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9and isoproterenol-induced preconditioning respectively by SB203580
pretreatment compared to values of 23.9±1.3 and 29.7±1.5 ml/min
respectively if no SB203580 was administered before any of the
preconditioning protocols.
The administration of noradrenaline 24h, but not 4h, prior to ischaemia has
been shown to result in enhanced contractile function in isolated perfused
rat hearts subjected to ischaemia and reperfusion (Meng et aI., 1993). It
also resulted in reduced arrhythmia severity following coronary artery
occlusion (Ravingerova et aI., 1995); marked increases in c-fos and c-jun
mRNA levels and increased in hsp70 gene expression (Meng et aI., 1995)
in delayed preconditioning. The noradrenaline activated, and U1-
adrenoreceptor-mediated, cardiac oncogene and stress protein gene
expression is believed to be responsible for the delayed protection. In
summary, catecholamine administration results in delayed protection of
the heart against myocardial ischaemia. To date there is no evidence that
f)-stimulation with isoproterenol can trigger delayed myocardial
preconditioning in the isolated rat heart.
1.1.4 Mediators of classic preconditioning with ischaemia
Whereas a trigger of preconditioning operates during the short ischaemic
period as well as the reperfusion following it, mediators are regarded as
those intracellular events that are vital to mediate protection during the
sustained ischaemic phase. There are 3 main candidate mediators in
classic preconditioning: p38 MAP kinase, the mitochondrial KATP channel
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(Downey et aI., 2001, Fryer et aI., 2001) and specific activated forms of
PKC (Downey, 1997a)
None of these candidate mediators can be explained by the synthesis of
new proteins. In fact, there is strong evidence against a role for gene
activation and protein synthesis:
(1) Preconditioning can be induced quickly, e.g. by 3 to 5 minutes of
ischaemia and 5 minutes of reperfusion.
(2) Inhibiting protein synthesis with cyclohexamide and RNA synthesis
with actinomycin D (Thornton et aI., 1990) have no effect on
preconditioning with ischaemia. This indicates that effective gene
activation has not occurred in the brief interval required to
precondition in classic preconditioning.
1.1.4.1 p38 MAP kinase and classic preconditioning
The role of p38 MAP kinase in classic PC has been investigated
extensively (Maulik et aI., 1998, Nakano et aI., 2000). Published
observations regarding the role of p38 MAP kinase in classic PC are
controversial and inconsistent. The two lines of studies performed thus far
have sought to determine whether (1) preconditioning induces the
activation of p38 MAP kinase during sustained ischaemia and (2) whether
inhibition of p38 MAP kinase abrogates the cardioprotective effects.
lt has been reported (Weinbrenner et al., 1997, Maulik et al., 1998,
Nakano et al., 2000) that phosphorylation of p38 MAP kinase during
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preconditioning is increased during sustained ischaemia. Weinbrenner and
collegues (1997) preconditioned rabbit hearts with 5 min ischaemia and
10 min reperfusion. They observed enhanced phosphorylation of p38 MAP
kinase after 10 and 20 minutes of index ischaemia in protected hearts. In
contrast, Ping et al (1999a) observed that p38 MAP kinase activation did
not correlate with the preconditioning effect, thereby questioning the
significance of p38 MAP kinase in preconditioning. Reports by 8aurin et al
(2000) also argued against a beneficial role for p38a MAP kinase
activation during sustained ischaemia: inhibition of p38a MAP kinase
during sustained ischaemia reduced reperfusion injury and contributed to
preconditioning induced cardioprotection. In our own laboratory it was
shown that the protective effect of preconditioning in rats was
accompanied by a reduced activation of p38 MAP kinase during 25 min
index ischaemia, and that the p38 MAP kinase inhibitor, 88203580,
protected effectively against ischaemic damage if infused prior to index
ischaemia in non-preconditioned hearts (Marais et aI., 2001). Further work
in our laboratory showed that p38 MAP kinase activated the small heat
shock protein, HSP27, and that this activation actually occurred during the
triggering phase of preconditioning (unpublished observations). The
precise role of p38 MAP kinase is thus unclear at the moment. Targeted
activation of individual p38 MAP kinase isoforms will be essential to
provide conclusive evidence to either support or refute the role of p38
MAP kinase in both classic and delayed PC.
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1.1.4.2 PKC as a mediator of classic preconditioning
Most of the agonists which generate the signal of (i.e. the triggers)
preconditioning bind to heptahelical transmembrane receptors (Sugden et
aI., 1995). The intracellular messenger systems linked to these receptors
are relatively well characterized and have now been investigated with
regard to myocardial preconditioning (Cohen & Downey, 1996). When an
agonist for example, adenosine or bradykinin binds, a receptor-coupled G
protein is activated (Cohen & Downey, 1996). This dissociates and in turn
activates a membrane bound phosholipase, which cleaves
phosphatidylinositol bisphosphate into inositol trisphosphate and
diacylglycerol (DAG). DAG then activates protein kinase C - this step is
believed to playa central role in ischaemic preconditioning. Protein kinase
C (PKC) is well placed to playa key role in cellular protection. It is known
to regulate numerous biological processes such as metabolism, myocyte
contraction, ion transport, gene expression and is coupled to the receptors
of many agonists of preconditioning (Cohen & Downey, 1996). Ping et al
(1997) reported PKCe translocation and activation during ischaemic
preconditioning, thus implicating an important role for it in the genesis of
classic preconditioning. The importance of PKCe translocation was
elegantly confirmed in experiments in transgenic mice (Saurin et aI.,
2002). These authors investigated whether preconditioning still occurred in
a mouse line lacking cardiac PKC-epsilon protein due to a targeted
disruption within the PKC-epsilon allele. Mice were preconditioned by 4 x 4
min ischaemia/6 min reperfusion, and then underwent 45 min of global
ischaemia followed by 1.5 h of reperfusion. In PKC-epsilon (-/-) hearts
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preconditioning failed to diminish infarction compared to controls (36.4±2.9
vs. 38.8±4.5%), whereas PKC epsilon (+/-) mice displayed partial
protection.
1.1.4.3 K ATP channels and classic PC
1.1.4.3.1 The primary functional role of mitochondrial K ATP channels
The K ATP channels have been described in many tissues including
pancreatic l3-cells, neurons, vascular smooth muscle, skeletal muscle and
cardiomyocytes. K ATP channels are closed by ATP in the low -micro-
molar-concentration range and open as ATP levels fall (Trapp & Ashcroft,
1997). The physiological function of K ATP channels remains conjectural,
but two such functions have been proposed. First, a concerted action of
the electrophoretic K+ uniport and the electro neutral K+/ H+exchange is
believed to maintain K+ homeostasis within the mitochondrion and
therefore control mitochondrial volume. The regulatory control of volume
changes is important for metabolic control at mitochondrial level
(Halestrap, 1989). Observations that ATP inhibits swelling, whereas K ATP
channels openers potentiate swelling, make it likely that this channel,
perhaps together with other K+ pathways, is involved in mitochondrial
regulatory volume changes. The respiring mitochondria transports H+, thus
generating both the transmembrane potential and the pH gradient. The
second putative role of mitochondrial K ATP channels is based on the
observation that energization of mitochondria is accompanied by uptake of
K+, which can be partially inhibited by glibenclamide and activated by
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potassium channel openers. This fact is consistent with the hypothesis that
K+uptake upon energization is responsible for partial compensation of the
electric charge transfer produced by the proton pump, thus enabling the
formation of il pH along with il 'P. Despite the fact that the mitochondrial
KATP channel has been characterized pharmacologically in cells, to date it
has not been cloned and its molecular structure remains unknown and its
very existence is questioned (Das et al., 2003, Lim et al., 2002).
1.1.4.3.2 Mitochondrial KATP channels as trigger and end effectors of
cardioprotection
Gross and Fryer (1999) reported that sulphonylurea receptor antagonist
could abolish ischaemie preconditioning induced protection, suggesting that
these channels might be effectors of cardioprotection. This idea was
reinforced by the observation that KATP channel openers like cromakalim
mimicked protection (Grover & Garlid, 2000).This indicated an important
trigger action of these channels.The exact mechanism through which
mitochondrial channel opening results in cardioprotection needs to be
investigated further.
The end effector(s) of ischaemic preconditioning have been very elusive.
Considerable evidence suggests that opening of K ATP channels represent
the final step in this signal transduction process. Evidence supporting the
KATP channels hypothesis is based on blockade of protective effects of
both ischaemic and pharmacological preconditioning by inhibitors of the
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KATP channels (Grover, 1997). Structurally diverse mitochondrial KATP
channel openers exert cardioprotective effects in various animal models of
ischaemia (Grover, 1994). These protective effects on ischaemie myocytes
are direct and independent of vasodilatory activity. These cardioprotective
effects are universally abolished by the KATP blockers such as
glibenclamide (Auchampach et aI., 1992a,).
There are, however, divergent views on the role of the mitochondrial KATP
channel as end effector. Thornton et al (1993b) were unable to prevent the
anti-infarct effect of preconditioning with glibenclamide in pentobarbital-
anaesthetized rabbits. However, with ketamine-xylazine anaesthesia of
rabbits, glibenclamide completely abolished protection (Walsh et aI.,
1994). The exact cardioprotective role of mitochondrial K ATPchannels is
not clear and needs to be investigated further.
1.2 Second Window Of Protection (SWOP)
1.2.1 Characteristics of the second window of protection as elicited by
ischaemia
The protective effect of ischaemie preconditioning has a bimodal
distribution. As stated above, the initial or classic window of
preconditioning begins within minutes of the initial preconditioning insult,
but is lost after 1-2h. (Li et aI., 1992, Murry et aI., 1986). However, 12-24h
following the preconditioning ischaemia or stimulus, a delayed phase of
protection can be observed (Kuzuya et aI., 1993). The protective effect of
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classic preconditioning is strong, but of limited duration (See Figure 1). In
contrast, this second window of protection (SWOP) (YelIon , 1995), is not
as powerful as the classic phase, but confers protection lasting for up to
72h (Marber et aI., 1993, Kuzuya et aI., 1993, Baxter et aI., 1997).
Following initial reports in dogs (Kuzuya et aI., 1993) and rabbit (Marber et
aI., 1993), delayed preconditioning against infarction in vivo has been
observed in most species examined so far (pig, rat and mouse). In almost
all studies, several cycles of preconditioning have been adopted, with an
index ischaemie insult of 30-60 minutes applied 24 hours later. Reduction
in infarct size with such protocols was around 45%. Miki et al (1999)
reported that in conscious rabbits, preconditioning induced a delayed
modest reduction in infarct size. However, others failed to demonstrate
delayed preconditioning against infarction studies in rabbits - Tanaka et al
(1994) demonstrated the protective effects of classic preconditioning in
this model (a 72% reduction in infarct size), but no protection was
observed 24 or 48 hours later. Delayed preconditioning has also been
demonstrated in large animals - Qui et al (1997b) examined the effects of
repeated brief coronary occlusions (2 x 10 minutes) in conscious pigs 24
hours before 40 minute occlusion. In the preconditioned group a modest,
26% reduction in infarct size was reported, which was not statistically
significant from controls in the study.
Delayed preconditioning has also been described in the rat, the
experimental animal used in our study. Yamashita et al. (1998b) showed
that preconditioning with two 3 minutes coronary artery occlusions, each
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separated by 5 minute reperfusion, protected against a 30 minute
occlusion 24 hours later. Infarct size was reduced by 34% in the
preconditioned group relative to the controls. In a subsequent study, the
same group reported that preconditioning with four 3 minute coronary
artery occlusions induced delayed protection with a 46% relative reduction
in infarct size (Yamashita et a/., 2000a).
The second window of protection confers protection against other
endpoints of injury apart from infarction such as reperfusion arrhythmias
and myocardial stunning. Global preconditioning of canine heart with four
5 minutes periods of rapid ventricular pacing resulted in marked protection
against coronary occlusion and reperfusion arrhythmias 20 hours later
(Vegh et a/., 1994). Reduction of stunning, another end point of delayed
preconditioning, has been described by the Bolli group (Sun et a/., 1995).
These workers used conscious pigs to investigate post-ischaemic
myocardial stunning lasting 3-4 hours. Repetition of the protocol in the
same animals 24 hours later revealed that post-ischaemic recovery of
contractile function was significantly accelerated compared with recovery
following the initial protocol. It therefore appeared that the initial stunning
protocol preconditioned against a subsequent stunning protocol 24h later.
1.2.2 Non-ischaemiedelayed PC
Delayed protection against myocardial ischaemia/reperfusion injury can be
induced by a wide variety of non-ischaemic stimuli, which can broadly be
classified as nonpharmacological and pharmacological. The former
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includes heat stress (Currie et aI., 1988), rapid ventricular pacing (Kaszala
et aI., 1996), and exercise (Yamashita et aI., 1999). Reports on infarction
demonstrate that non-ischaemie delayed preconditioning protects similarly
to ischaemie delayed PC.
1.2.3 Pharmacological stimuli of delayed PC
Pharmacological agents that can elicit delayed preconditioning consist of
naturally occurring and often noxious agents such as endotoxin (Brown et
aI., 1989), interleukin-1 (Brown et aI., 1990), TNFa (Brown et aI., 1992),
TNF-13 (Nelson et aI., 1995), leukemia inhibitory factor (Nelson et aI.,
1995), ROS (Sun et aI., 1995), and of clinically applicable drugs such as
NO - releasing agents (Takano et aI., 1998b) , adenosine receptor
agonists (Baxter et aI., 1994), endotoxin derivatives such as
monophosphoryl lipid A [MLA] (Yoa et aI., 1993) and opioid receptor
agonists (Fryer et aI., 1999).
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Short ischaemie
periods
(Preconditioning)
Longer lasting
ischaemie
period
1-180 min
"Early phase"
24-72 h •
"Late phase"
Figure 1.1: A schematic illustration of experimental protocols for early and late
preconditioning (white = ischaemia, blue = ischaemia)
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1.2.4 Triggers of delayed preconditioning
Brief myocardial ischaemia and ensuing reperfusion are associated with
major metabolic perturbations that result in generation of a wide variety of
metabolites and ligands. These substances warn the myocardium that a
danger is imminent, essentially acting as a cellular alarm system to which
the heart responds by switching to a defensive phenotype.
1.2.4.1 Adenosine
Adenosine has long been proposed as a "regulatory metabolite" in
ischaemia (Bern et aI., 1963), in recognition of its ability to limit myocardial
oxygen demand by causing negative inotropy and chronotropy and by
increasing oxygen delivery through vasodilation.
The concept that adenosine released during the PC stimulus triggers the
development of delayed protection was first proposed by Baxter et al
(1994). Activation of the adenosine receptors protects against infarct size,
but is neither necessary nor sufficient to trigger late PC against stunning
(Sun et al., 1995, Auchampach et aI., 1999, Maldonado et al., 1997).
Whether only one or both of these adenosine receptor subtypes (A1 and
A3) contributes to triggering ischaemia-induced late preconditioning is still
unknown, because 8-p-(sulfophenyl) theophylline (the only adenosine
receptor antagonist shown to block the development of late
preconditioning after ischaemie stress) (Baxter et al., 1994) is not selective
for either of the two receptors. The adenosine agonist z-chioro-N"
cyclopentyladenosine (CCPA) is highly selective for A1 receptors. Baxter
and co-workers (1994) were the first to demonstrate adenosine receptor
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involvement in the delayed phase of myocardial protection 24h after
ischaemic preconditioning.They also demonstrated the temporal nature of
this delayed effect with adenosine A1 receptor agonist, which lasted up to
72 hours (Baxter et al., 1997) Recent studies indicate that delayed
protection against infarction can also be triggered by a selective
adenosine A3receptors agonist (Takano et aI., 2001). Thus, it appears that
pharmacological stimulation of either A1 or A3 receptors can elicit late
preconditioning against infarction.
The majority of pharmacological studies imply an anti-ischaemic effect of
acute adenosine A3 receptor activation (Liu et aI., 1994, Armstrong and
Ganote, 1994, Armstrong and Ganote, 1995, Carr et al., 1997,
Auchampach et aI., 1997, Tracey et aI., 1997, Dougherty et aI., 1998).
Although recent evidence suggests that the protective actions of A3
receptor agonists could be mediated by A1 receptor activation, this has not
been conclusively proven (Guo et aI., 2001). Takano et al (2001) have
undertaken the pharmacological and molecular characterisation of
adenosine receptor participation in delayed protection. They reported that
the A3 receptor agonist IB-MECA (100 or 300 f.!g/kg),given to rabbits 24h
before coronary artery occlusion, resulted in limitation of infarction,
comparable to that seen with the A1 agonist, CCPA.
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1.2.4.2 NitricOxide
The first indication that NO triggered late PC was provided by a study in
which administration of f\F-nitro-L-arginine (L-NA), a nonselective inhibitor
of all 3 NO synthase(NOS) isoforms (neural (nNOS), endothelial (eNOS)
and inducible( iNOS), before the PC ischaemic stimulus was found to
block the development of delayed protection against myocardial stunning
(Bolli et al., 1997). A subsequent study demonstrated that NO was also
necessary to trigger ischaemia induced late preconditioning against
myocardial infarction (Qui et al., 1997). Pre-treatment with NO donors in
the absence of ischaemia induced a delayed protective effect against both
myocardial stunning and infarction that was indistinguishable from that
observed during the late phase of ischaemic preconditioning (Takano et
al., 1998, Banerjee et al., 1999, Guo et al., 1999 and Hili et al., 2000).
Administration of nitroglycerine can elicit late PC both by the intravenous
and transdermal route (Hili et al., 2000), and this effect is not abrogated by
the development of nitric tolerance, indicating that different mechanisms
underlie the haemodynamic and preconditioning actions of nitrates (Hill et
al., 2000). The ability of NO - releasing agents such as nitrates to faithfully
mimic late phase of ischaemie PC despite nitrate tolerance supports the
possibility of novel clinical applications of these drugs.
Recent studies (Xuan et al., 2000) have provided direct evidence of
enhanced biosynthesis of NO in myocardium subjected to brief episodes
of ischaemia/reperfusion. The source of increased NO formation during
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the PC ischaemia is likely to be eNOS, since the development of late PC is
blocked by pretreatment with the nonselective NOS inhibitor L-NA, but not
with the relatively selective iNOS inhibitors aminoguanidine and S-
methylisothiourea (Bolli et aI., 1997).
Interestingly, the development of ischaemie late PC is not affected by
pretreatment with the guanylate cyclase inhibitor ODa (Kodani et aI.,
2000) but is completely prevented by pre-treatment with the antioxidant
mercaptopropionyl glycine (MPG)(Takano et aI., 1998, Tang et aI., 1997).
NO is known to react rapidly with O£ to form peroxynitrite anion (ONOO"),
which then protonates and decomposes to generate the hydroxyl radical
('OH) or some other potent oxidant with similar reactivity (Bechman et aI.,
1990 , Crow et aI., 1995). Because MPG scavenges both ONOO" and
'OH(Crow et aI., 1995, Sun et aI., 1993), the ability of MPG to block late
preconditioning (Takano et aI., 1998, Tang et aI., 1997) coupled with the
failure of ODa to do so, (Kodani et aI., 2000) suggest that NO triggers this
response via formation of (ONOO") and/ or secondary ROS, rather than
via cGMP-dependent pathways.
In the rabbit, Dana et al (2002) found that the NO synthase inhibitor nitro-
L-arginine methyl ester (L-NAME) administered prior to an adenosine A1
agonist did not prevent the development of tolerance to ischaemia,
suggesting that adenosine A1 receptor activation and NO are independent
co-activators of the delayed ischaemie preconditioning response.
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1.2.4.3 Reactive Oxygen Species and delayed PC
The concept that the generation of ROS during the PC ischaemia was
essential to trigger delayed protection was first proposed by Sun et al
(1996). These investigators demonstrated in conscious pigs that the
administration of a combination of the antioxidants superoxide dismutase
(SOD) plus catalase plus MPG during the initial ischaemie challenge
prevented the development of late preconditioning against stunning.
Similar findings were obtained in rabbits with MPG alone. (Tang et al.,
1997). MPG has also been found to prevent ischaemia-induced late PC
against infarction (Yamashita et al., 1998), arrhythmias (Yamashita et al.,
1998), and coronary endothelial injury (Kaeffer et aI., 1997), as well as
heat stress-induced (Yamashita et al., 1998) and exercise-induced
(Yamashita et al., 1999) late preconditioning against infarction. These
findings implicate ROS as initiators of these forms of delayed protection as
well. Conversely, intracoronary infusion of a ROS-generating solution in
rabbits elicits a late PC response (Takano et al., 1997). Taken together,
these results suggest that sublethal oxidative stress plays a useful role by
triggering delayed cardioprotection. Further studies will be necessary to
determine the source(s) and the identity of the ROS responsible for
initiating the late PC, and whether NO and ROS are parts of the same
mechanism (i.e. whether ROS are derived from the reaction of NO with O2,
as discussed above) or act in parallel as an independent trigger.
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1.2.4.4 Opioids
The evidence for a role for opioids in delayed preconditioning is still
limited, but a number of studies have recently shown that opioids can act
as a trigger for this phenomenon. Recent data in rats (Fryer et aI., 1999)
and mice (Guo et aI., 2000) indicate that pharmacological activation of 01-
opioid receptors induces a delayed infarct-sparing effect 24 to 48 hours
later. In this regard Gross and colleagues (1999) demonstrated that 01-
opioid receptor agonist (TAN-167) induced protection via activation of
mitochondrial KATPchannels as cardioprotection was abolished by 5HD but
not glibenclamide. It was demonstrated that protection was dependent
upon 01 receptor stimulation immediately following administration of the
opioid agonist and upon receptor reoccupation immediately prior to index
ischaemia (Fryer et aI., 1999). Opioids are thought to mediate
cardioprotection in rats (Fryer et aI., 2001), pigs (Schulz et aI., 1998) and
rabbits (Miki et aI., (1998) It was later shown that this cardioprotective
effect was mediated by activation of the MAP kinases, ERK and p38 MAP
kinase. These ongoing studies are important, as the use of agents such as
01-opioid receptor agonists may be of clinical relevance in the setting of
patients with acute coronary symptoms who are at risk of myocardial
ischaemia
1.2.4.5 Bradykinin
Bradykinin is well established as a mediator of classic preconditioning and
there is limited evidence to suggest that it may also contribute to delayed
preconditioning. Ebrahim et al (2001) have shown that administration of
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bradykinin to rats caused very brief haemodynamic perturbation «60
seconds) but resulted in protection against infarction 24 hours later. If
these rats were pre-treated with L-NAME to inhibit NO synthase activity
prior to bradykinin administration, the protective effect 24 hours later was
abolished. Further indirect evidence for a role of endogenous bradykinin
liberation in delayed preconditioning in pigs comes from work by
Jaberansari et al (2001), who showed that a 2 min coronary artery
occlusion was insufficient to induce delayed myocardial protection 24
hours later. However, if an angiotensin converting enzyme inhibitor was
given prior to this sublethal threshold preconditioning stimulus, a fully
protective response was observed. This finding is compatible with the
notion that bradykinin, whose breakdown is inhibited by ACE-inhibitors, is
a mediator of delayed preconditioning. To date, no work has reported the
effects of bradykinin receptor antagonists in delayed preconditioning
models. Such observations are required to confirm that endogenous
bradykinin participates in triggering delayed preconditioning.
1.2.4.6 Delayed cardioprotection by administration of catecholamines
Historically, studies resulting from cathecholamine administration almost
certainly represent the earliest examples of delayed cardioprotection. Of
particular interest was the finding that myocardial resistance developed
against toxic doses of isoprenaline not only if rats were pretreated with
smaller doses of isoprenaline ( Rona et aI., 1963) but that coronary artery
ligation, either of the left or the right coronary artery, also protected against
the toxic effects of isoprenaline (Selye et aI., 1960). This phenomenon,
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referred to by Rona (Dusek et aI., 1971) as myocardial resistance or
protection, was not associated with beta-receptor down regulation and
lasted several days or even weeks (Joseph et aI., 1983). It has not been
possible to determine whether at this time these workers attempted to
demonstrate whether isoprenaline also protected against the
consequences of coronary artery occlusion, but this was demonstrated
several years later (Beckman et al., 1981). Beckman and colleagues
observed that dogs that developed long- term tolerance to intravenously
administered adrenaline were also resistant to coronary embolization with
microspheres (Beckman et al., 1981). For example, only 1 of 14 tolerant
dogs fibrillated on coronary artery occlusion compared to 11 of 31 in the
control group; all deaths occurred early, that is within 15 minutes of
occlusion. The time course of this delayed protection was not evaluated.
1.2.5 Mediators (or effectors) of late preconditioning
Ischaemic preconditioning causes an increase in the rate of myocardial
protein synthesis. If this increase is blocked by cyclohexamide; the
development of delayed preconditioning is also blocked (Rizvi et aI.,
1999). Thus, unlike early preconditioning, late preconditioning requires
increased synthesis of new proteins, not simply activation of pre-existing
proteins. The time course of the enhanced tolerance to ischaemia, which
requires 12 to 24 hours to develop and lasts for 3 to 4 days, (Tang et aI.,
1996, Baxter et aI., 1997) is also consistent with the synthesis and
degradation of cardioprotective proteins. Several proteins have been
proposed as possible mediators (effectors) of the protection afforded by
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late preconditioning including NOS, cyclooxygenase-2 (COX-2), aldose
reductase, antioxidant enzymes (particularly Mn SOD), and heat stress
proteins (HSP's).
Nitric Oxide Synthase
The first demonstration that the cardioprotective effects of the late phase
of ischaemie PC are mediated by NOS was provided by studies in
conscious rabbits, in which delayed protection against both myocardial
stunning (Bolli et aI., 1997) and infarction (Takano et aI., 1998) was found
to be completely abrogated when preconditioned animals were given L-NA
24 hours after ischaemie PC, just before the second ischaemie challenge.
The same effects were observed with the relatively selective iNOS
inhibitors aminoguanidine and S-methylisothiourea, implicating iNOS as
the specific NOS isoform involved in mediating the protective effects of
late preconditioning (Bolli et aI., 1997, Takano et aI., 1998). These results
were subsequently confirmed by others (Imagawa et aI., 1999).
Using an in vivo murine model of myocardium infarction, Guo et aI., (1999)
demonstrated that the late phase of ischaemie PC was associated with
upregulation of myocardial iNOS (whereas eNOS remains unchanged).
Furthermore, that targeted disruption of the iNOS gene completely
abrogated the delayed infarct sparing effect, providing unequivocal
molecular genetic evidence for an obligatory role of iNOS in the
cardioprotection afforded by the late phase of ischaemie PC.
Immunohistochemical and in situ hybridization studies identified cardiac
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myocytes as the specific cell type that expressed iNOS during late
preconditioning (Wang et al., 2000). Thus, NO appears to playa dual role
in the mechanism of the delayed ischaemie preconditioning, acting initially
as the trigger (Takano et al., 1998, Bolli et al., 1997, Hili et al., 2000) and
subsequently as the mediator (Bolli et al., 1997, Takano et al., 1998,
Imagawa et al., 1999, Guo et al., 1999, Wang et al., 2000) of this adaptive
response. This concept has become known as the "NO hypothesis of late
preconditioning" (Bolli et al., 1998). The finding that bath ischaemie
preconditioning and nitroglycerin induce a rapid increase in steady-state
levels of iNOS mRNA, which is abolished by administration of L-NA before
ischaemia (Jones et al., 1999), is congruent with the concept of NO -
dependent iNOS induction. Taken together, the studies reviewed above
(Takano et al., 1998, Bolli et al., 1997, Qiu et al., 1997, Banerjee et al.,
1999, Guo et al., 1999, Hili et al., 2000, Xuan et al., 2000, Bolli et al.,
1997) support a complex paradigm in which 2 different NOS isoforms are
sequentially involved in the pathological cascade of late PC, with eNOS
generating the NO that initiates the development of the late PC response
on day 1 and iNOS then generating the NO that protects against recurrent
ischaemia on day 2 (Bolli et al., 1998). The quantitative aspects of the
upregulation of iNOS after ischaemie PC are noteworthy. The increase in
cardiac iNOS protein expression in the Guo et al (1999) study was mild: 18
fold less than that observed after a lethal dose of lipopolysaccharide.
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Figure 1.2: Schematic presentation of the role of nitric oxide in delayed
preconditioning
This supports the hypothesis (Guo et al., 1999) that induction of iNOS after
ischaemie PC is protective because it is relatively modest, in contrast to
other situations (such as inflammation or septic shock) in which iNOS
induction is massive and promotes tissue injury. The precise
mechanism(s) whereby iNOS -derived NO protects against ischaemia
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remains to be elucidated, but appears to involve activation of guanulate
cyclase, given that both the alleviation of stunning and the reduction in
infarct size are abrogated if 000 was administered on day 2.
Administration of 000 on day 1 did not alleviate the infarct sparing effects
(Kodani et aI., 2001).
Besides ischaemia-induced PC, there is now evidence that other forms of
late PC are also iNOS dependent. Guo et al (1999) found that the delayed
infarct -sparing effects elicited by S -nitroso - N -acetylpenicillamine and
nitroglycerine (Guo et aI., 1999), the selective 01- opioid receptor agonist
TAN- 670, (Guo et aI., 2000) and by exercise (Y, Guo and R.Bolli,
unpublished observations, 2000) were completely abrogated in iNOS -1-
mice. This implies that iNOS serves as an obligatory mediator of NO
donor-induced, 01-opioid receptor induced, and exercise induced late PC
against infarction. Similarly, iNOS activity has been found to be necessary
for the delayed infarct size limitation observed after pre-treatment with the
endotoxin derivatives MLA and RC-552 (Xi et aI., 1999, Zhao et aI., 1997)
and diazoxide (Ockaili et aI., 1999).
Recent reports on the role of iNOS in CCPA - induced late PC have
arrived at conflicting conclusions (Guo et aI., 2000, Zhao et aI., 2000, Bell
et aI., 1999). Administration of CCPA 24 hours prior to a lethal ischaemie
insult resulted in a marked reduction of infarction (Kukreja et aI., 2000).
However, Bell and co-workers (2002) demonstrated that iNOS knockout
mice (with no demonstrable iNOS protein) display a similar degree of
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infarct limitation following CCPA administration 24 hours earlier. This study
is in contrast to findings of others (Bolli al., 1997) and implies that delayed
cardiac protection can be achieved via an iNOS independent mechanism.
Clearly, the relationship between adenosine-induced late PC and the role
of iNOS in this scenario needs to be further investigated.
1.2.5.2 Cyclooxygenase
An obligatory role for COX-2 in late PC was first shown by Shinmura et al
(2000). Utilising conscious rabbits, this study found that COX-2 protein
expression was upregulated 24 hours after ischaemic preconditioning,
concomitant with an increase in the myocardial levels of prostaglandin
(PG) E2. 6-keto-PGF1a. Administration of 2 unrelated COX - 2 - selective
inhibitors (NS - 398 and celecoxib) 24 hours after ischaemie
preconditioning abolished the increase in prostanoids and completely
blocked the cardioprotective effects of late PC, demonstrating that COX-2
activity is necessary for this phenomenon to occur (Shinmura et aI., 2000).
Similar results were subsequently obtained in mice (Guo et aI., 2000).
These observations identify COX-2 as a cardioprotective protein and
strongly point to PGE2 and/or PGb as the likely effectors of COX-2-
dependent protection. Induction of COX-2 is generally thought to be
detrimental (Vane et aI., 1998). The finding that COX-2 mediates the anti-
stunning and anti-infarct effects of late PC impels a reassessment of
current views regarding this enzyme and supports a more complex
paradigm in which COX-2 can play either a beneficial or a deleterious role
depending on various factors (e.g., the intensity of its induction, the
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pathophysiological setting, and the ability of specific cell types to
metabolize PGH2 produced by COX-2 into cytoprotective prostanoids)
(Shinmura et aI., 2000).
The recognition that iNOS and COX-2 are co - induced and serve as co -
mediators of late PC logically leads to the question of whether there is an
interaction between these 2 proteins or whether they act as independent
effectors of cytoprotection. Previous studies have suggested that NO can
directly activate COX-2 (Salvemini et aI., 1993). Further work is needed to
confirm all the above findings.
1.2.5.3 Aldose Reductase and delayed myocardial protection
Oxidative stress, osmotic stress, cytokines and NO are known to
upregulate the expression of aldose reductase, an enzyme that catalyzes
not only the metabolism of glucose to sorbitol, but also the detoxification of
ROS - derived lipid aldehydes (Srivastava et aI., 1998). Shinmura et al
(2000) have recently found that the protein expression of aldose reductase
is upregulated 24 hours after ischaemic PC in conscious rabbits and that
inhibition of this enzyme abrogates the infarct-sparing effects observed in
untreated animals. Thus, in addition to iNOS and COX-2, aldose reductase
is a third candidate for mediator of cardioprotective actions of the late
phase of ischaemie PC. The mechanism whereby aldose reductase
enhances resistance to ischaemia/reperfusion remains to be determined
but could involve the removal of toxic byproducts of lipid peroxidation such
as 4-hydroxy-trans-nonenal (Srivastava et aI., 1998).
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1.2.5.4 Antioxidant enzymes and delayed preconditioning
The oxidants, superoxide and/or hydrogen peroxide, are generated as a
consequence of normal cellular aerobic metabolism (Sies, 1991). Since
these oxidants participate in reactions which result in cytotoxicity,
detoxification of these oxidants is a prerequisite for successful aerobic life.
Mammalian cells contain superoxide dismutase (SOD) (which
decomposes superoxide), and glutathione peroxidase and catalase, which
decompose hydrogen peroxide. These antioxidant enzymes prevent
excessive accumulation of oxidants during normal aerobic metabolism. UR
is one pathologic event which disturbs this oxidant/antioxidant balance
(Reilly et al., 1991, Korthuis and Granger, 1993). In general, it is believed
that the oxidant production upon reperfusion of ischaemie tissues
overwhelms the detoxifying capacity of the enzymatic antioxidants and
initiates a cascade of events that eventually leads to tissue injury.
Exogenous administration of SOD and/or catalase offers protection
against I/R-induced tissue injury in a variety of in vivo and in vitro models
(Granger 1988, Kvietys and Granger, 1997). Thus it is not surprising that
consideration has been given to the possibility that delayed
preconditioning is in part, a result of an enhanced antioxidant status of
tissue or cell. Evidence for this idea comes from extra cardiac tissue. In
the gut, mucosal epithelial barrier dysfunction was induced by IIR; an
event that was completely prevented by a previous (24 h earlier) I/R
challenge (Osborne et al., 1994). The antioxidant status of the mucosa
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was increased (increased activities of SOD, glutathione peroxidase and
catalase) at 24h, but not at 1 and 72 hours after initialllR challenge.
These findings indicate that the development of delayed preconditioning is
associated with an enhanced antioxidant status of the target tissue (gut
mucosa of rat). There is evidence that delayed preconditioning induced by
IIR is specific for oxidant stress. In the gut, an initial insult imposed 24h
earlier protected against hydrogen peroxide-induced, but not acid- or
ethanol-induced mucosal epithelial barrier dysfunction (Osborne et aI.,
1994). A similar phenomenon was noted in the kidneys, where an IIR
insult resulted in an enhanced antioxidant status of the glomeruli and
prevented the typically observed proteinuria induced by a subsequent
exogenous administration of hydrogen peroxide (Yoshioka et aI., 1990).
Similar correlation between the development of delayed preconditioning
and an enhanced antioxidant status have been demonstrated in the kidney
and heart (YelIon and Baxter, 1995, Steare and Yellon, 1995). In the heart,
I/R-induced myocardial stunning (Sun et aI., 1996) and decreased
responsiveness of coronary arteries to acetylcholine (Kaeffer et aI., 1997)
were largely prevented by a previous IIR insult. The induction of this
delayed preconditioning was largely attributed to the generation of oxidant
stress during initiaiIIR challenge. Exposing isolated cardiomyocytes to
anoxialreoxygenation (AIR; the in vitro equivalent to IIR) results in
superoxide generation by the myocytes (Zhou et aI., 1996). Twenty-four
hours later myocyte Mn-SOD was increased and a subsequent AIR
challenge no longer resulted in superoxide production by the myocytes. In
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addition, delayed preconditioning was evident, in that the second AIR
challenge no longer resulted in myocyte cytotoxicity (LDH release). The
delayed preconditioning was prevented in this system by exposing the
myocytes to Mn-SaD during the initial AIR challenge. Delayed
preconditioning could also be induced if the myocytes were initially
exposed to superoxidelhydrogenperoxide generating system (xanthine
plus xanthine oxidase) rather than AIR. Finally, exposure of endothelial
cells in culture to hydrogen proxide results in (1) an increase in SOD,
catalase, and glutathione peroxidase; and (2) protection against the
cytotoxic effects of the second challenge with hydrogen peroxide 18-24h
later (Lu et aI., 1993). Taken together, these studies indicate that an initial
IIR insult results in an oxidative stress which enhances the target tissues
antioxidant status and provides a specific protection against a second
oxidant stress, i.e. IIR.
The induction of antioxidant enzymes may be an important mechanism
involved in delayed preconditioning, though the relative contribution of
specific antioxidant enzymes is unclear. The importance of catalase in
protecting the myocardium against IIR - induced injury (as measured with
infarct size and creatinine kinase release) is provided by studies using
transgenic mice ( Li et aI., 1997). The hearts from isolated transgenic mice
in which myocardial catalase is increased 60-fold (while SOD glutathione
peroxidase was unchanged) were resistant to IIR injury.
Studies in dogs have shown that ischaemie preconditioning induces an
increase in the protein expression and activity of Mn-SOD 24 hours later
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while other antioxidant enzymes are unchanged (Hoshida et aI., 1993) and
that the time course of Mn-SOD induction parallels that of protection
against lethal ischaemia/reperfusion injury (Kuzuya et aI., 1993). A similar
association between the time course of Mn-SOD induction and that of
delayed cardioprotection has been observed after heat stress (Yamashita
et aI., 1998), exercise ( Yamashita et aI., 1999) and administration of
CCPA ( Dana et aI., 1998). In one study however, (Xi et aI., 1998) heat
stress did not augment Mn-SOD activity. The increase in Mn-SaD activity
after heat stress and exercise appears to be caused by the production of
ROS, TNF-a and interleukin -1 f3 (Yamashita et aI., 1999 , Yamashita et aI.,
1998 , Yamashita et aI., 2000). Importantly, in vivo administration of
antisense oligonucleotides to Mn-SOD has been reported to block heat
stress induced (Yamashita et aI., 2000), exercise induced (Yamashita et
aI., 1999), and CCPA induced (Dana et aI., 2000) delayed PC, indicating
that Mn-SOD upregulation is essential for these 3 forms of delayed
cardioprotection. No such data are available to determine whether Mn-
SOD is necessary for ischaemia induced late PC in vivo (although
evidence supporting this concept has been obtained in isolated neonatal
myocytes) (Yamashita et aI., 1994). In contrast to this finding, in isolated
rat cardiac myocytes, delayed preconditioning appears to be strongly
dependent on induction of Mn-SOD. When hypoxia/reperfusion was used
as a challenge, delayed preconditioning was associated with an increase
in cellular Mn-SOD (Yamashita et aI., 1994)
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An increase in activity of various antioxidant enzymes (Mn-SOD ,Cu-ZN
SOD, catalase and/or glutathione peroxidase) has also been reported 24
to 72 hours after pharmacological PC with interleukin-1 (Maulik et aI.,
1993), and endotoxin (Maulik et aI., 1995), concomitant with increased
myocardial resistance to ischaemia/surperfusion injury, but a cause-and-
effect relationship remains to be established.
Not all studies have found upregulation of antioxidant defenses during late
preconditioning. In conscious pigs (Tang et aI., 1997) and rabbits (Tang et
et., 2000) subjected to ischaemie PC, no increase in anti-oxidant enzymes
(Mn-SOD, Cu-ZN SOD, catalase, glutathione peroxidase or, glutathione
reductase) activity could be detected 24 hours after PC stimulus, when the
delayed cardioprotection was fully manifest. Thus, the role of antioxidant
proteins in ischaemia induced late PC remains unclear.
1.2.5.5 Heat stress Protein and delayed preconditioning
Studies in transgenic mice overexpressing HSP70 have shown that this
protein confers protection against ischaemia/reperfusion injury, (Plumier
et et., 1995, Marber et et., 1995, Radford et aI., 1996). However, it remains
controversial whether ischaemie or pharmacological PC upregulates HSPs
in vivo. Earlier investigators reported an increase in myocardial HSP70
content 24 hours after ischaemie preconditioning (Marber et et., 1993,
Knowlton et aI., 1991). Subsequent studies found no HSP70 induction in
rabbits preconditioned with ischaemia, (Baxter et aI., 1998), CCPA (Baxter
et el., 1997, Heads et aI., 1998, Bernado et et., 1999) or monophosphoryl
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lipid A (MLA) (Yoshida et aI., 1996, Baxter et aI., 1996). Furthermore,
several studies in rats subjected to whole body hyperthermia (Yamashita
et aI., 1997 ,Qian et aI., 1998 ,Kukreja et aI., 1999) or to ischaemie
preconditioning (Qian et aI., 1999) have shown that the changes in
myocardial HSP70 and HSP27 content do not correlate with protection
against infarction. In addition, induction of HSP70 by heat stress fails to
confer cardioprotection in mice (Xi et aI., 1998).
Recently heat shock protein 27 (HSP27), has been suggested to
participate in late preconditioning. Studies in rabbits have shown that
CCPA-induced late PC is associated with a redistribution of HSP27 from
the membranous to the cytosolic fraction of the homogenate (Heads et aI.,
1998) as well as with increased phosphorylation of this protein. The latter
is abolished by pre-treatment with protein kinase C -(PKC) or tyrosine
kinase inhibitors (Dana et aI., 2000). Since HSP 27 is a substrate for the
p38 MAP kinase pathway, which is activated 24 hours after CCPA (Dana
et aI., 2000) it has been proposed that posttranslational modification of
HSP27 may play an important role in mediating the delayed
cardioprotection afforded by CCPA (Dana et aI., 2000).
The evidence reviewed above suggests the induction of the heat shock
proteins is responsible for the cardioprotection of delayed preconditioning.
Whether only the small (HSP27) or large (HSP 70) or both of these
proteins participate in delayed myocardial preconditioning needs to be
investigated further.
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1.2.5.6 KATPChannels
There is persuasive evidence that the opening of KATPchannels is an
important mechanism of classic preconditioning as discussed earlier, but
what is the evidence for its participation in delayed PC? Bernado et al
(1999) reported that delayed preconditioning was abolished when either
glibenclamide (which antagonize opening of sarcolemmal KATPchannels)
or 5-HD (which antagonize opening of mitochondrial KATPchannels) was
administered prior to ischaemia. This suggests a critical role for KATP
channels opening in delayed myocardial protection. However, it has been
concluded that the sarcolemmal, and not the mitochondrial KATPchannels
were more important, since they elicited differences in monophasic action
potential duration. In this regard Cole et al (1991) demonstrated that
glibenclamide, a nonselective KATPchannel antagonist, attenuated the
action potential duration shortening, which occurs during ischaemia. Work
done by Tanako and collegues (2000) have confirmed that 5-HD given
prior to index ischaemia abolished delayed preconditioning against
infarction but did not alter the anti-stunning effect of preconditioning. A
further interesting development is that KATPchannel openers such as
diazoxide are able to induce pharmacological delayed preconditioning
(Ockaiti et al., 1999, Takano et aI., 2000).
Takashi et al (1999) have reported that diazoxide triggered delayed
preconditioning via a PKC dependant mechanism. This group found that
pretreatment with diazoxide (7mg/kg i.v.) 12, 24 and 72 hours before
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ischaemia/reperfusion resulted in a significant reduction in infarct size.
This cardioprotection against infarction was blocked if hearts were
pretreated with 5-HD (5mg/kg i.v.) and the PKC blocking agent
chelerythrine (5mg/kg i.v.) on the first day before diazoxide pretreatment or
10 minutes before IIR on the second day. This group therefore concluded
that activation of mitochondrial KATP channel with diazoxide produced late
preconditioning against reperfusion injury. The mitochondrial KATP
channels may play an important role in delayed myocardial adaptation but
its precise role remains to be elucidated.
1.2.6 The signaling pathway of delayed preconditioning
The stimuli (mentioned above) trigger late PC by activating a complex
cascade of signalling events that ultimately results in increased
transcription of cardioprotective genes. Among various families of cellular
kinases, there is now convincing evidence that PKC and Src protein
tyrosine kinases (PTKs) play an essential role in the development of late
PC (See Fig 1.3 a and b).
1.2.6.1 Protein Kinase C
The notion that PKC is essential for the genesis of late PC was first
proposed by Baxter et al (1995), who found that the delayed infarct-
sparing effects of ischaemie preconditioning in rabbits was abrogated by
pre-treatment with the PKC inhibitor chelerythrine. Conversely,
administration of the PKC activator dioctanoyl-sn-glycerol induced
cardioprotection 24 hours later (Baxter et al., 1997). Subsequent studies
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have also implicated PKC in the development of CCPA-induced (Dana et
aI., 1997) and heat stress- induced (Yamashita et aI., 1997, Kukreja et aI.,
1999, Joyeux et aI., 1997) late PC against infarction. Direct evidence that
PC stimuli activate PKC in vivo, however, was lacking. Furthermore, no
information was available as to which PKC isoform was involved.
These issues were addressed in a series of studies in conscious rabbits
(Ping et aI., 1997, Qui et aI., 1998, Ping et aI., 1999, Ping et aI., 1999) in
which it was found that ischaemic PC caused selective translocation (and
activation) (Ping et aI., 2000) of PKCe and PKC11(2 members of the
subfamily of novel PKC isoforms) but does not affect the other 8 isoforms
expressed in the rabbit heart (PKC isoforms a, [3, y, 8, t, S A and Il) and
does not significantly change total PKC activity (Ping et al., 1997).
Inhibition of PKCe translocation (and activation) by chelerythrine blocked
the development of late PC against myocardial stunning (Ping et aI.,
2000), whereas inhibition of PKC11translocation did not have an effect,
indicating that the translocation of PKCe (but not PKC 11)was necessary
for late PC to occur (Qui et aI., 1998). Thus, activation of PKC after
ischaemic preconditioning is isoform selective, and PKCe appears to be
the specific PKC isotype responsible for the development of delayed
cardioprotection.
The ischaemic preconditioning induced activation of PKCe is caused by
the generation of NO during the initial ischaemic stress, as it is blocked by
pre-treatment with L-NA (Ping et aI., 1999). Interestingly, administration of
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NO donors in the absence of ischaemia induces a selective activation of
PKCe quantitatively similar to that induced by ischaemie preconditioning
(Ping et a/., 1999). This event is essential for NO donor - induced late
preconditioning, since co-administration of chelerythrine blocks both the
activation of PKCe and delayed protection elicited by the NO donors (Ping
et a/., 1999). Thus, the recruitment of the e lsoforrn of PKC is a critical
signalling event in the development of both ischaemia - induced and NO
donor - induced late preconditioning in rabbits. The recent finding that
transgenic expression of constitutively active PKCe mimics both the
signaling events and the cardioprotective effects of late PC supports a role
of PKCe in mice as well (Ping et a/., 2000).
The precise mechanism whereby NO activates PKCe remains to be
elucidated. Because MPG blocks NO donor-induced late PC (Takano et
a/., 1998), it seems reasonable to postulate that NO-derived reactive
species (ONOO- and! or ROS) may activate PKCe either by direct
oxidative modification or via activation of phospholipases (Ping et a/.,
1999).
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Figure 1.3a: Schematic illustration showing activation of intracellular signalling
pathways during classic and delayed preconditioning. DAG, Oiacyl
glycerol; MAPK, Mitogen-activated protein kinases; PIP2, Phosphatidyl
inositol diphoshate; PKC, Protein kinase C; PLC, Phospholipase C;
PLO, Phospholipase 0; TK, Tyrosine kinase
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Fig 1.3 b I3-Adrenergic signalling in cardiomyocytes. Gs, stimulatory G-protein;Gi
inhibitory G-protein; AC, Adenylyl cyclase; PKA; Protein kinase A; MAPK,
Mitogen activated protein kinase; ATP, Adenosine triphosphate; , cAMP,
cyclic adenosine monophosphate.
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1.2.6.2 Protein tyrosine kinases
Since more than a 1000 different PTK's have been identified so far,
assessing the contribution of this class of enzymes to late preconditioning
represents a gargantuan task. A role of PTK's in the genesis of ischaemia
- induced late PC was proposed on the basis of studies using genistein (a
tyrosine kinase inhibitor) (Imagawa et a/., 1997), which, however, is a
broad inhibitor of most known PTKs and other kinases. Recent studies in
conscious rabbits (Ping et a/., 1999 , Dawn et a/., 1999) have focused on 2
major families of PTKs - the Src PTKs and the epidermal growth factor
(EGF) receptor PTKs. It was found that ischaemic PC selectively activates
2 members of the Src PTKs (Src and Lck) (among the 7 members
expressed in rabbit heart) and that this activation is blocked by
chelerythrine, suggesting that these kinases are distal to the activation of
PKC (Ping et a/., 1999). Inhibition of Src and Lck activation with
lavendustin (LD-A) completely abrogates the development of late PC
against myocardial stunning (Dawn et a/., 1999), indicating that Src and lor
Lck signaling plays a causative role in this phenomenon. In contrast, EGF
receptor PTK's are not activated by ischaemic preconditioning (Ping et a/.,
1999). Thus, Src andlor Lck (but not EGF receptor PTK's) appear to be
essential components of the signalling pathway responsible for the
development of ischaemia induced late PC and appear to be downstream
targets of PKC phosphorylation in rabbits. Subsequent studies in mice
have corroborated these concepts by demonstrating that Lck is a direct
substrate of PKC E (Song et a/., 2000) and that the targeted disruption of
the Lck gene abolishes ischaemia induced late PC (Ping et a/., 2000). LD-
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A has also been found to block CCPA - induced late PC (Dana et aI.,
1997) implicating tyrosine kinases in the genesis of this form of adaptation
as well. In contrast, genistein failed to block heat stress - induced late PC
(Joyeux et aI., 1997).
1.2.6.3 Mitogen-ActivatedProtein Kinases
Another potential downstream target of PKC - dependent signaling during
the development of late PC is the MAPK superfamily, which includes 3
major subfamilies, the p44/p42 MAPKs (or extracellular signal - regulated
kinases [ERKs]), p38 MAP kinases, and the p46/p54 MAPK (or c-jun N-
terminal kinases [JNKs]. Several studies in hearts have documented that
brief myocardial ischaemia/ reperfusion is associated with activation of
p44/42 MAPKs, p38 MAP kinases and JNK (Sugden et aI., 1998 , Ping et
aI., 2000) but it is unknown whether the ischaemic protocols used in those
investigations elicit late preconditioning. Recent studies in conscious
rabbits have demonstrated that an ischaemic protocol known to induce
delayed cardioprotection activates all of the 3 MAPK subfamilies, although
the activation of p38 MAP kinase is of short duration (Ping et aI., 1999,
Ping et aI., 1999). The activation of p44/p42 MAPKs and JNKs is
abolished by chelerythrine, indicating that it is downstream of, and
dependent on, activation of PKC (Ping et aI., 1999, Ping et aI., 1999).
Interestingly, selective overexpression of PKC c in adult rabbit myocytes
induces activation of p44/p42 MAPKs and protects against simulated
ischaemia, an effect that can be abolished by p44/p42 MAPK inhibitors
(Ping et aI., 1999).
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Among the mitogen -activated protein (MAP) kinase families, the role of
stress activated kinase, p38 MAP kinase, has received special attention in
relation to adenosine A1 receptor induced delayed protection. Adenosine
treatment of the isolated rat heart was observed to cause rapid
phosphorylation of MAP kinase - activated protein kinase - 2 (MAPKAPK-
2, a downstream substrate of p38 MAP kinase) (Nakano et al., 2000).
Dana et al (2000) observed that myocardial p38 MAP kinase catalytic
activity was markedly elevated 24h after treatment with CCPA. This
increase in p38 activity correlated with phosphorylation of the small heat
shock protein, H8P 27. The time course of this p38 MAP kinase induction
is unknown as is the identity of the active isoenzyme and the mechanisms
of its regulation. It is also unknown if this apparent increase in p38 MAP
kinase activity was sustained throughout the period following A1 agonist
stimulation until the period of protection 24-72 hours later. If this was not
the case, it remains to be determined how this late increase in kinase
activity occurred in the absence of any reinforcing stimulus such as
ischaemia (Ping et al., 2000).
In support for a role of p38 MAP kinase are the findings by Kukreja et al
(2001), that 88203580 given prior to CCPA abolished the late protection
afforded by CCPA in the isolated mouse heart. It is of particular interest
that in this study A1 receptor associated delayed protection required the
phosphorylation of p38 MAP kinase at two time points: as an early event
following CCPA administration and also as a late event during the
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ischaemie episode 24h later. Enhanced phosphorylation of p38 MAP
kinase during index ischaemia was observed in the hearts from mice
pretreated with CCPA 24h earlier. This differs from the observation of
Dana et al (2000) who reported an increase in the basal activity of p38
MAP kinase before regional ischaemia. This enhanced phosphorylation of
p38 MAP kinase correlated with protection against infarction because
88203580 and genistein given before CPPA abolished and also blocked
the phosphorylation of p38 MAP kinase during the subsequent ischaemia.
Another intriguing observation was that late phosphorylation of p38 MAP
kinase in CCPA-pretreated hearts was abolished by 5-hydroxydecanoate
(5-HD) given at the time of index ischaemia, suggesting that opening of
the mitochondrial KATPchannel participated in the distal signalling
mechanism. This implies coupling between mitochondrial KATPand p38
MAP kinase in delayed preconditioning.
The critical unresolved issue now is whether the recruitment of the MAPKs
contributes to the development of late PC or whether it is merely an
epiphenomenon. Elucidation of this issue will require studies in an in vivo
model of late preconditioning in which the activity of MAPKs is inhibited
either with transgenic approaches (e.g., gene targeting or transgenesis of
dominant - negative mutants) or with pharmacological agents more
specific than currently available compounds such as 88202190.
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1.2.6.4 Role of Kinases in Mediating Protection
In addition to their role in initiating the development of late PC shortly after
the stimulus (day 1), there is mounting evidence that cellular kinases are
also necessary for the protection to become manifest 24 hours later (day
2). This concept is supported by the recent finding that administration of
the PTK inhibitor LD-A before the second ischaemic challenge (on day 2)
completely abrogates the protective effects of late preconditioning against
myocardial stunning and concomitant increase in iNOS activity ( Dawn et
aI., 1999). It appears; therefore, that PTKs play a bifunctional role in
ischaemia induced late PC, contributing not only to its development shortly
after the initial ischaemic stress but also to the occurrence of the
protection 24 hours later. The mechanism whereby PTKs participate in the
protection on day 2 remains to be established. Because inhibition of PTKs
with L- DA on day 2 abolishes the increase in iNOS activity, it has been
suggested that posttranslational modulation of iNOS proteins via tyrosine
phosphorylation is necessary to activate this enzyme and to confer
tolerance to ischaemia/reperfusion injury (Dawn et aI., 199B). In addition
the recent finding that p3B MAPK activity is markedly increased 24 hours
after administration of CCPA (concomitant with increased phosphorylation
of HSP27) raises the possibility that this subfamily of MAPKs may be
involved in mediating the protective effects of late preconditioning (Dana et
a/.,2000).
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1.2.7 Transcription factors
The recruitment by the preconditioning stimulus of PKC, Src PTKs, and
other as-yet-unidentified kinases leads to the activation of transcription
factors that govern the expression of the cardioprotective genes
responsible for delayed preconditioning. The first transcription regulatory
element to be identified as an integral component of the late
preconditioning response was nuclear factor-K-B (NF-K-B) (Xuan et ai.,
1999), which is known to be a major modulator of iNaS, COX-2, and
aldose reductase gene expression. Using conscious rabbits, Xuan et al
(1999) demonstrated that ischaemie preconditioning induces rapid
activation of NF-K-B and that this event can be mimicked by infusing NO
donors in the absence of ischaemia. Inhibition of NF-K-B with di-
ethyldithiocarbamate completely abrogated the cardioprotective effects
observed 24 hours later, indicating that NF-K-B plays a critical role in the
genesis of late PC (Xuan et ai., 1999). The ischaemie PC- induced
activation of NF-K-B was blocked by pre-treatment with L-NA, MPG,
chelerythrine and LD-A (all given at doses previously shown to block late
PC), indicating that the cellular mechanism whereby ischaemie
preconditioning activates NF-K-B involves the formation of NO and ROS
and the subsequent activation of PKC- and PTK- dependent signalling
events (Xuan et ai., 1999). Thus, NF-K-B appears to be a common
downstream pathway through which multiple signals elicited by ischaemie
stress (NO, ROS, PKC, and PTKs) act to induce gene expression in the
heart. Subsequent studies have shown that ischaemie PC induces both
serine and tyrosine phosphorylation of I-K-Ba (the inhibitor of NF-K-B)
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concomitant with PKC - dependent activation of IKKa and IKK13(the serine
-threonine kinases that phosphorylate I-K-Ba (Zhang et aI., 1999),
suggesting that a dual mechanism accounts for the activation of NF-K-B
induced by ischaemia, as this event is absent in Lck -/- mice (Ping et aI.,
2000).
A molecular link between PKCE (the isoform implicated in the genesis of
late preconditioning) (Ping et aI., 1997, Qiu et aI., 1998, Ping et aI., 1999)
and NF-K-B is further supported by studies in adult cardiac myocytes, in
which selective overexpression of PKCE has been found to induce
activation of NF-K-B (Li et aI., 2000), activation of IKKa and IKK13(Li et aI.,
1997) and serine tyrosine phosphorylation of I-K-Ba (Li et aI., 1997).
Interestingly, PKCE - induced recruitment of NF-K-B in cardiomyocytes is
abolished by inhibition of either p44/p42 MAPKs or JNKs (Li et aI., 2000).
Recruitment of NF-K-B has also been reported in rat hearts subjected to
short-term protocols of ischaemia/ reperfusion in vivo (Chandrasekar et aI.,
1997) and in vitro (Maulik et aI., 1998) but it is not clear whether these
protocols elicit a late preconditioning response in the models used. In
addition, activating protein 1 (AP-1) has been found to be activated by
brief myocardial ischaemia in rats (Chandrasekar et aI., 1997) and by
overexpression of PKCE in cardiomyocytes (Li et aI., 2000). Whether this
transcriptional factor plays a functional role in the development of the late
PC response remains unknown. Given the fact that specific combinations
of 2 or more trans-regulatory proteins are obligatorily required for iNOS
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gene expression and given the mutiplicity of enzymes that co-mediate late
PC (e.g. COX-2, aldose reductase and MN-SOD), it seems likely that the
upregulation of iNOS, COX-2 and other co-mediators after a
preconditioning stimulus involves simultaneous activation of multiple
stress-responsive transcription factors acting in an additive or synergistic
manner.
1.2.8 Summary of delayed preconditioning
A complex sequence of cellular events is mobilized by the heart in reaction
to stress such as ischaemia. The heart elicits both early and delayed
protective response. The exact cellular and molecular mechanisms
underlying the phenomenon of delayed preconditioning remains to be
deciphered, but remarkable progress has been made in understanding this
powerful protective adaptation as discussed above. It is now clear that this
delayed adaptation is a polygenic process that requires the synthesis of
multiple proteins. Chemical signals released by ischaemic stress (such as
NO, ROS, and adenosine) are transduced by a cascade of signalling
elements that includes protein kinase C and NF-K-B to the nucleus where
they direct the transcription of iNOS, COX-2, aldose reductase, and other
cardioprotective genes. An analogous sequence of events (probably
involving MnSOD) can be triggered by a wide variety of stimuli, including
heat stress, exercise, and cytokines. Delayed preconditioning appears to
be a universal reponse of the heart in response to stress. A sustained
cardioprotection similar to that afforded by the late phase of ischaemie PC
can also be induced pharmacologically with clinically relevant agents, such
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as NO donors, adenosine A1 and A3 receptor agonists, endotoxin
derivatives and 81-opioid receptor agonists. This suggests that this
endogenous adaptive response might be exploited for therapeutic
purposes in treating patients exposed to myocardial ischaemia.
1.3 Melatonin effects on the heart
1.3.1 Physiology and pharmacology
In humans the pineal gland lies in the center of the brain, behind the third
ventricle. The gland consist of two cell types: pinealocytes, which
predominates and produce both indolamines (mostly melatonin) and
peptides (such as arginine and vasotocin), and neuroglial cells. The gland
is highly vascular.
Melatonin, or acetyl-N-formyl-5-methoxytrypamine was first identified in
bovine pineal extracts on the basis of its ability to aggregate melanin
granules and thereby lighten the color of frog skin (Lener et ai., 1958). In
the biosynthesis of melatonin, tryptophan is first converted by tryptophan
hydroxylase to 5-hydroxytryptophan, which is decarboxylated to serotonin.
Melatonin synthesis is catalized by two enzymes (arylalkylamine N-
acetyltransferase and hydroxyindole-O-methyltransferase) that are largely
confined to the pineal gland (Axelrod and Weissbach , 1960).
The mammalian pineal gland is a neuroendocrine transducer. The photic
information from the retina is transmitted to the pineal gland through the
suprachiasmatic nucleus of the hypothalamus and the sympathetic
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nervous system. The neural input to the gland is norepinephrine, and the
output is melatonin. Melatonin synthesis is stimulated by darkness and
inhibited by light. With onset of darkness, the photoreceptors release
norepinephrine, thereby activating the system, and the number of o1-and
131-adrenergicreceptors in the gland increases (Pangerl et aI., 1990). The
activity of arylalkylamine N-acetyltransferase, the enzyme that regulates
the rate of melatonin synthesis, is increased, initiating the synthesis and
release of melatonin. Melatonin is rapidly metabolized by the liver via
hydroxylation (6-hydroxymelatonin). It is conjugated with sulphuric or
glucuronic acid and excreted in the urine.
1.3.2 Mechanism of action of melatonin
Melatonin partially synchronises circadian rhythmicity in the heart rate
during constant light conditions (Witte et aI., 1998). In the rat heart,
tyrosine hydroxylase activity is highest at early night and acetylcholine
synthesis peaks in the afternoon (Brusco et aI., 1998). The above rhythms
deteriorate with ageing and melatonin may partially restore the
deteriorated rhythms (Brusco et eï., 1998). In in vitro systems, melatonin
has an anti-adrenergic effect causing a decrease in contractility of the
isolated rat papillary muscle (Abete et aI., 1997) and decreases
ischaemia/reperfusion - induced arrhythmias in the isolated rat heart (Tan
et aI., 1998). This indole also supresses the iron-induced lipid peroxidation
in many rat tissues including the heart (Tang et aI., 1997). The
cardiomyopathic hamster develops heart disease leading to congestive
heart failure early in life. Inhibition of pineal function prolonged the life
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span of this animal with congenital congestive heart failure (Natelson
et aI., 1997).
1.3.3 Direct melatonin actions on the heart: antioxidative actions
The modern concept of the free radical theory of ageing suggests that free
radicals influence the primary and several secondary age- associated
ageing processes such as carcinogenesis, decline of immune function,
atherosclerosis, and heart diseases. With ageing, there is a shift in the
antioxidative/prooxidative balance that leads to increased oxidative stress,
dysregulation of cellular function, and ageing (Meydani et aI., 1998).
Melatonin has a significant antioxidative action. Accumulated evidence
suggests that it may be beneficial for the ageing heart, arteriosclerosis and
heart disease.
Melatonin is an electron-rich molecule. It may interact with free radicals to
form metabolites (e.g. N-acetyl-N-formyl-5methoxykynuramine and n-
acetyl-5-methoxykynuramine) which are also effective free radicals
scavengers. These continuous processes of trapping of unpaired electron
free radicals by melatonin and its metabolites have been defined as a
scavenging cascade reaction (Reiter et aI., 2000). The stable end-products
such as cyclic-3-hydroxymelatonin radical (Equation 1) are excreted. (Tan
et aI., 1999, Tan et aI., 1998) Alternatively, melatonin may stimulate
several antioxidative enzymes such as glutathione peroxidase, glutathione
reductase, glucose-6-phosphate dehydrogenase and superoxide
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dismutase and inhibit the prooxidative enzyme, nitric oxide synthase
(Reiter et aI., 1999 , Reiter et aI., 2000, Tan et aI., 1999 , Tan et aI., 2000)
Melatonin + 2 HOo~ 3-0H-melatonin + H20 ----------------(Equation 1)
The protective antioxidant capacity of melatonin has been implicated to be
responsible for:
(1) The reversal of Ca2+ - stimulated ATP-ase activity reduced by alloxan
in the rat myocyte in vitro (Chen et aI., 1994 a, Chen et aI., 1994 b).
(2) An increase in glutathione peroxidase, a detoxyfying enzyme, in the
chick heart (Pablos et aI., 1995).
(3) The protective effect against adriamycin-induced cardiomyopathy in
rats (Morishima et aI., 1998).
(4) A suppressive action on the iron-induced lipid peroxidation by
reducing the concentration of cellular membrane malondialdehyde of
the rat heart cell membrane (Tang et aI., 1997).
(5) The prevention of ischaemia/reperfusion-induced arrythmias in the
isolated rat heart (Tan et aI., 1998).
The protective action of melatonin on the isolated model indicates clinical
application of melatonin in patients with coronary heart diseases. In
addition to melatonin, other methoxyindoles such as 5-methoxytryptamine
also have radioprotective actions (Lebkova, 1966 , Feher et aI., 1968,
Hara et et aI., 1997). 5-Methoxytryptamine and other methoxyindoles are
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present in the serum, pineal gland and retina of animals (Tsang et a/.,
1996 , Li et a/., 1997a, Li et a/., 1997b , Zawilska et a/., 1998 , Vivien et a/.,
1999). 5-Methoxyindoles are potent antioxidants and melatonin is a
relatively safe molecule with potential for many clinical applications
(Bubenik et a/., 1998) and little side effects in humans.Therefore, the
protective effect of melatonin and/or its analogues on coronary heart
diseases should be further examined in animal models and human
studies.
1.3.4 Direct melatonin actions on the heart : cardiac melatonin receptor
mediated actions
In addition to its antioxidative actions (Tan et a/., 1998), there is evidence
for receptor mediated melatonin actions. Melatonin receptors were
characterized in the duck, quail and chick heart using the melatonin
radioligand, 2C25I]iodomelatonin for radioreceptor studies on membrane
preparations, as well as autoradiography and immunohistochemistry on
tissues sections. The 2[125I]iodomelatonin binding to bird heart membranes
was rapid, saturable, stable, reversible, of high affinity and low density and
modulated by the nonhydrolyzed GTP analog, guanosine 5'-0-(3-
thiotriphosphate) (Pang et a/., 1993 , Pang et a/., 1996 , Pang et a/., 1998).
Similar results were obtained with fish hearts ( Pang et a/., 1994). In
addition, Paul et a/ (1999) reported the binding of 2C25I]iodomelatonin to
the hamster heart.
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The biochemical and pharmacological characteristics of hamster
2C25I]iodomelatonin binding sites remains to be investigated. The
picomolar affinity receptors in birds and fish correlates well with the
circulating levels of melatonin indicating that these binding sites in chick
myocytes are physiological melatonin receptors (Pang et aI., 1993, Pang
et aI., 1996, Pang et aI., 1998, Pang et aI., 1994). Moreover these
receptors are highly specific for melatonin, melatonin analogues (2-
iodomelatonin, 6-chloromelatonin and melatonin) and naphthalenic
ligands (N-[2-(7-methoxy-1-naphthyl)ethyl] cyclobutane
carboxamide;s20642; N-propyl-N--[2-(7-methoxy-1-naphthyl) ethyl]
urea:s20753; N--[2-(7-methoxy-1-naphthyl)ethyl :S20750] (Pang et aI.,
1993 , Pang et aI., 1996 , Pang et aI., 1998 , Pang et aI., 1994).
Using a specific antibody (anti-mt1) against the third intramembrane loop
(TIL3) of the human melatonin receptor rnt- (Song et aI., 1997, Chan et
aI., 1997), it has been estimated that the molecular weight of the
immunoreactive protein (melatonin receptor) was 35 kOa by Western
blotting ( Pang et aI., 2000). To date no melatonin receptors have been
identified in human myocardium.
Alternately, the target tissues of melatonin was detected as early as 8 day
old chick embryonic brain (Chong et aI., 1992), earlier than the
development of the melatonin synthesizing enzyme, NAT. Whether the
early appearing receptor is functional is not known. The melatonin receptor
is expressed early (embrionic day 11) in the chick heart (Song et al., 1995)
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and brain (Song et al., 1997), before the appearance of NAT (Zeman et
al., 1990). Its peak density, expressed either as per mg protein or f.lgDNA,
is around embrionic day 15 (Pang et al., 2000) which coincides with the
appearance of melatonin rhythm and also when adrenergic and
cholinergic innervation are fully functional in the embryonic heart (Pappano
et al., 1974). This is true for glucocorticoid receptors in the chick heart.
However, among all melatonin target tissues in the chicken, the heart is
the only tissue that expresses melatonin receptors most abundantly in its
embryonic stage. Those of the kidney, spleen and brain peaked at 2
weeks, 2 days and 3 months posthatched respectively (Chong et al., 1992,
Song et al., 1995).
The biological significance of these cardiomyocyte melatonin receptors
remains to be elucidated. Melatonin affected [Ca2+/Mg2+] -dependent
ATPase (Ca2+pump) activities in the sarcolemma of rat heart tissue in vivo
and in vitro (Chen et al., 1993 , Chen et al., 1994a , Chen et al., 1994 b).
Ca2+ plays an important role in normal physiology. In view of the above
Mei et al (2000) studied the effect of melatonin on calcium current in the
chick embryonic myocyte, where 2[1251] iodomelatonin binding sites have
been demonstrated (Pang et al., 2000).They demonstrated that melatonin-
induced increase in high-voltage calcium current may increase myocyte
contractility and enhance cardiac output. Therefore, a regulatory role for
melatonin on cardiac function should be considered further.
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1.3.5 Effects of melatonin on ischaemia and reperfusion injury
Melatonin has significant protective effects against the cardiac damage
and altered physiology that occur during ischaemia/reperfusion injury
(reviewed recently by Reiter & Tan, 2003). These actions were apparent
even when melatonin was given as a single dose. Tan et al (1998) used a
Langendorf isolated perfused rat heart model. The left descending
coronary artery was ligated for 10 minutes, which reduced the total
coronary flow by more than 25%. A 10 minute reperfusion period was
allowed during which most hearts (80 to 90%, respectively) exhibited
premature ventricular contractions (PVC) and/or ventricular fibrillation
(VF). When melatonin was infused throughout the period of occlusion and
after reopening the coronary artery it significantly reduced both PVC and
VF. The melatonin concentration in the perfusate was either 1,10 or 50
f.lM. Anticipating that the effects of melatonin in this study were likely
related to its antioxidant actions, Tan et al (1998) infused another free
radical scavenger i.e. vitamin C as a positive control in a separate group of
hearts. At a concentration of 500 f.lM (i.e. 500 times melatonin
concentration) ascorbate was significantly less effective than melatonin in
preventing the cardiac arrhythmias in this model.
Investigations regarding the antioxidant actions of melatonin are
increasing. Work done in our laboratory (Salie et aI., 2001) did a thorough
in vitro analysis of melatonin action in a setting of the
hypoxia/reoxygenation in cardiomyocytes. Adult cardiomyocytes were
isolated and grown in culture and chemical hypoxia was induced by the
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addition of 1.5 mM KCN and 20 mM deoxyglucose to the superfusion fluid.
Cells were then preloaded with either tetramethylrhodamine (TMRM) in
combination with either dichlorodihydrofluorescein (DCDHF),
dihydrorhodamine 123 (DHR) or Fluo 3 to determine the effects of
melatonin on H202, ROS and Ca2+respectively using the confocal
microscope. Chemical hypoxia resulted in significantly increased H202.
ROS and Ca2+ fluorescence. Melatonin at doses 50 and 100 J-LM
significantly reduced all these changes. These findings strongly implicate
and support the antioxidant and protective properties of melatonin. Kaneko
and workers (2000) used the isolated perfused working heart model, and
subjected hearts to 30 minutes ischaemia followed by a 30 minutes of
reperfusion. In this study melatonin concentration in the perfusion medium
was 100 J-LM.This group also found a significant reduction in the duration
of ventricular tachycardia relative to the duration of these arrhythmias in
control hearts. Additionally, melatonin significantly restored the functional
recovery of the left ventricle (LV) : LV developed pressure ,+dp/dt and -
dp/dt were 63.0, 60.3 and 59.4 respectively compared to the values of the
controls - 30.2, 29.7, 31.5 respectively. They then further extended their
study by measuring OH' generation (by estimating levels of 2,3 -
dihydroxybenzoic acid after salicylate administration) and observed a
highly significant reduced amount of metabolite in the perfusate in
melatonin treated hearts. At the end of reperfusion, tissue myocardial
levels of lipid peroxidation products were measured. Melatonin again
reduced the levels of lipid peroxidation in the heart significantly. This
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study concluded that melatonin was beneficial during IIR and the results
were consistent with the free radical scavenger actions of melatonin.
Lagneux et al (2000) recently published their findings in which both
melatonin and an analogue, 5-methoxy-carbonylamino-N-acetyl tryptamine
(5-MCA-NAT), were compared in terms of their efficiencies in reducing
both reperfusion arrhythmias and infarct volume after IIR. Rats were
treated with melatonin (1 or 10 mglkg i.p.) or with 5-MCA-NAT (10 mglkg
i.p.) 30 minutes before the hearts were perfused using the Langendorff
method. In terms of both the reperfusion arrhythmias and infarct size, this
group reported that melatonin and 5-MCA-NAT both provided 'spectacular
protection' against IIR injury. Taking in to consideration the large amount
of experimental evidence implicating free radicals in cardiac arrhythmias
during hypoxialreoxygenation (Shiki & Hearse, 1987)., Lagneux et al
(2000) surmised that free radical scavenging activity of melatonin
accounted for the ability to restore cardiac function. However since the role
of free radicals in determining infarct size is some what less clear (Jeroudi
et al., 1994) the authors were cautious in assuming that the reduction in
the size of the lesion was exclusively related to this indole's antioxidant
properties.
Lee et al (2002) performed the first in vivo study in which melatonin was
tested for its ability to protect the heart when blood supply was transiently
interrupted. A bolus intravenous injection of either 0.5,1.0, 5.0 mglkg was
administered before left coronary artery occlusion. Melatonin markedly
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suppressed ventricular tachycardia and fibrillation and also reduced the
total number of PVC's upon reperfusion. Finally, while eight of the nine
rats subjected to ischaemia/reperfusion died, none of those treated with
melatonin died.
Most studies reported cardiac protection if protocols included melatonin
pretreatment. Only a few studies conducted with pretreatment of melatonin
reported no myocardial protection. For example, Dave et al (1998)
conducted a study in which anaesthetized rabbits were treated with
melatonin 10 mg/kg intravenously 10 min before coronary artery occlusion.
All rabbits underwent 30 minutes of occlusion and 3 hour reperfusion. The
control rabbits received vehicle. Melatonin at this dose had no limiting
effect on infarct size (0.38 ± 0.06, compared to the controls, 0.34 ± 0.07).
Effects of melatonin are summarizes in Table 1.1
Stellenbosch University http://scholar.sun.ac.za
Table 1.1: A literature review of melatonin function during ischaemia/reperfusion
injury
Model Duration of I/R (min) Melatonin actions Reference
Langendorf model (rat) 10/10 Reduced premature ventricular Tan et al., 1998
contraction and fibrillation
Langendorf model (rat) 30/30 Reduced ventricular Kaneko et al., 2000
tachycardia and fibrillation;
Restored ventricular function;
Reduced lipid peroxidation;
lowered OH' generation
Langendorf model (rat) 5/30 Reduced reperfusion Lagneux et al., 2000
arrythmias; reduced infarct
size
Langendorf model (rat) 20/40 Reduced fibrillation Szarszoi et al., 2001
In situ heart (rat) 45/60 Reduced ventricular Lee et al., 2002
tachycardia and fibrillation;
Lowered total ventricular
contractions,reduced 02 and
MPO activity, lowered infarct
size, increased survival
In situ heart (rat) 7/7 Reduced ventricular fibrillation, Sahna et al., 2002
Lowered mortality
In situ heart (rat) 3/120 Reduced infarct size Sahna et al., 2003
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In situ heart (rabbit) 30/180 No improvement in cardiac Dave et ai., 1998
,
function, no reduction in
infarct size
Cardiomyocytes in culture(rats) 12.5 or 27.5/1.5 Reduced morphological Salie et al., 2001
damage, lowered oxygen free
radical generation , reduce
[Ca2+] i
--~
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1.4 Motivation and aims of study
Evidence exist that adenosine, nitric oxide, reactive oxygen species and
opioids elicit both classic and delayed preconditioning. It has been
established in our laboratory that transient l3-adrenergic stimulation with
isoproterenol mimics classic ischaemic preconditioning (Lochner et a/.,
1999). Beta-adrenergic stimulation increases both nitric oxide (Balligand et
a/., 1999) and reactive oxygen species generation (Opie et aI., 1979). The
mechanism of delayed preconditioning includes both NO synthesis and
ROS production (Bolli 1999). In view of this it is plausible that isoproterenol
could elicit delayed preconditioning. However, to date there is no evidence
that l3-stimulation with isoproterenol can trigger delayed myocardial
preconditioning in the isolated rat heart.
We hypothesise that:
(1) Beta-adrenergic stimulation with isoproterenol can elicit delayed
myocardial preconditioning.
(2) The mechanism of beta-adrenergic preconditioning mediated
delayed preconditioning will include nitric oxide synthesis and
generation of radical oxygen species.
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1.4.1 The specific aims of this study was as follows
(1) To set up a model for second window of protection using beta-
adrenergic stimulation with isoproterenol
(2) To establish whether beta-adrenergic preconditioning was mediated
by NOS activation and NO release (using the non-selective NOS
inhibitor, Nw-nitro L-arginine, L-NA)
(3) Investigate whether beta-preconditioning with isoproterenol protects
via ROS generation or ROS mediated mechanisms by eliciting
delayed PC in the presence of ROS scavengers such as melatonin,
MPG and N-acetyl-cysteiene.
(4) Due to the findings obtained in (3) a substudy was done in which the
protective effects of melatonin and specifically its ability to protect the
myocardium after oral administration, was investigated
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Chapter 2
Material and Methods
2.1 Animals
Male Wistar rats weighing 250-350 grams were utilized in this study.
Institutional ethical guidelines were observed with respect to the handling
of experimental animals. Rats were allowed free access to food and water.
All animals were weighed in order to determine the correct dose for body
weight before the intraperitoneal administration of isoproterenol,
melatonin, L-nitro arginine, MPG or NAC. Injection volume did not exceed
3ml for any drug mentioned. Pentobarbital (50mg/kg) was administered
intraperitoneally before excision of hearts.
2.2 Perfusion technique (Fig. 2.1)
At the end of the experimental protocol all hearts were rapidly excised and
arrested in ice-cold (4°C) normal saline solution. These hearts were then
mounted on the aortic cannula and perfused retrogradely in a
noncirculating manner at 1DOemH20 for 15 minutes to allow stabilization
of the heart. The left atrium was cannulated to allow atrial perfusion (atrial
pre-load 15 emH20) according to the working heart model of Neely as
modified by Opie and coworkers (1971). When switched to working heart
perfusion, the left ventricle ejected against a hydrostatic pressure of
1DOemH20. Myocardial temperature was thermostatically controlled by
inserting a temperature probe into the pulmonary artery and was checked
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15'L 10' WH 5'L 35' RI 10'L 20'WH
Stabilization Regional Ischaemia Reperfusion
Langendorffl Retrograde mode
Working heart model Antegrade mode
Regional ischaemia
Fig. 2.1 Perfusion protocol after completion of treatment protocols
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at regular intervals to ensure that it remained constant during the
experiment.
2.3 Perfusion buffer
A modified Krebs-Henseleit bicarbonate buffer was used containing (in
mM/I) NaCI 119, NaHC0325, KCI 4.7, KH2P041.2, MgS04.7H20 0.59,
Na2S040.59, CaCI2H20 1.25 and Glucose 10.
2.4 Regional ischaemia
Hearts were perfused for a control period of 30 minutes -15 min
retrogradely and 10 minutes in a working heart (antegrade) mode. Hearts
were then perfused retrogradely for 5 minutes, after which a silk suture
was inserted underneath the proximal LAD. After measuring coronary flow
the suture was tightened and the LAD occluded for 35 minutes at 36.5°C.
Coronary flow was measured again at the beginning of regional ischaemia
and a 33% reduction in coronary flow in comparison to the 15 minute
control coronary flow period indicated adequate regional ischaemia.
Another confirmation of regional ischaemia was regional cyanosis of
myocardial surface. Reperfusion consisted of 10 minutes retrograde and
20 minutes working heart perfusion. Perfusion protocols will be described
in the experimental protocol section (2.7) below.
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2.5 End· pointsof ischaemiedamage
2.5.1 Myocardialfunction
The coronary (Oe) and aortic (Oa) flow rates in ml/minute were measured
manually. The aortic pressure was obtained through a side-arm of the
aortic cannula which was connected to a Viggo-Spectramed pressure
transducer and was recorded in mm Hg. The peak systolic pressure (PSP)
and heart rate (HR) were obtained from the recordings made. Total work
was determined according to the formula of Kannengieser et al. (1979). To
determine functional recovery of all hearts the post - ischaemie aortic
output was expressed as a percentage of pre - ischaemie aortic output.
2.5.2 Determinationof infarctsize as end point
Following regional ischaemia and reperfusion the silk suture under the left
anterior descending coronary artery branch was reoccluded. A 0.25%
Evans blue solution was infused into the remaining coronary bed using a
sterile syringe to delineate the area at risk. Hearts were removed and
frozen. After 24 hours the frozen heart was cut into transverse slices of
2mm thickness. After slices had thawed, they were stained by incubation
for 20 minutes in a 1% triphenyl tetrazolium choride buffer (TTC) with a pH
of 7.4. Tetrazolium reacts with NADH and dehydrogenase enzymes and
causes all vital tissue still containing the enzymes and co-factors to stain a
deep red color. The infarcted area (dead tissue) of the heart remains
unstained. After staining was completed, the slices were fixed by
immersion in a 10% formalin solution. The heart slices were then
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sandwiched between two glass plates to a uniform 2 mm thickness. The
region of infarcted tissue and the risk zone was traced in each ventricular
section. The volume of infarcted tissue and risk zone of each heart was
calculated by multiplying the planimetered areas with the slice thickness
and summing the products (Summa sketch II, Summa graphics). Infarct
size was expressed as a percentage of zone at risk for infarction.
2.6 Chemicals, drugs and reagents
Melatonin (5-methoxy -N-tryptamine), isoproterenol, N-acetyl -cysteine and
L-NA (Nw L-arginine) were purchased from Sigma (St. Louis, MO, USA).
The melatonin radioimmunoassay test kit was obtained from Amersham.
MPG (mercaptopropionyl-glysine) was obtained from Aldrich (St.Louis,
USA).
2.7 Treatment protocols
Delayed preconditioning was elicited by intraperitoneal administration of
isoproterenol 24 hours before induction of sustained regional ischaemia.
The effect of pharmacological manipulations was studied 24h later by
subjecting all hearts to regional ischaemia as described in 2.4.
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2.7.1 Eliciting Delayed Beta-Adrenergic Preconditioning with isoproterenol
- dose finding study (Figure 2.2)
Group 1: No previous treatment
Group 2: Two repeated intraperitoneal administrations of isoproterenol
(0.04mg/kg) 3 hours apart.
Group 3: One intraperitoneal injection of isoproterenol ( 0.04mg/kg).
Group 4: Two intraperitoneal administrations of isoproterenol (0.02mg/kg)
three hours apart.
Group 5: Four repeated administrations of isoproterenol dose
(0.004mg/kg) intraperitoneally, at one hour intervals.
Group 6: Four injections of isoproterenol (0.0004 mg/kg) also at 1 hourly
intervals.
2.7.2 Investigating the role of NO in f3 - adrenergic delayed preconditioning
(Fig.2.3)
To investigate whether f3 - adrenergic delayed preconditioning was
mediated through NO generation, the non - selective NOS inhibitor (L-NA)
was administered an hour before preconditioning with isoproterenol
Group 1 : No previous treatment
Group 2 : Pre-treatment with 17.5 mg/kg L-NA 24 hours before regional
ischaemia
Group 3 : Four injections of isoproterenol dose (0.0004 mg/kg) also at 1
hourly intervals.
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Group 1
Group 2
Group 3
Group4
Group 5
Group 6
24h~afteOrl~fil~__t rc~==========:J -'injecti~n
--------~-----;~==IT----1
I 3b I ~ ~~=====~ ____.. .. 2XO.04Iso i.p -/
1" 1XO.04 Iso i.p
35 min RI 30 min Rep
I 3b I....~~~~~-----~~=====T-----~
Pbl I I
........ 4XO.004lso . -/I.p
lIb I I It tt t 4XO.0004lso i.p /----- C::_==-==--=====:J~--
t Administration of isoproterenol
i Determination of infarct size by TIC staining
Fig. 2.2 Experimental protocols for optimal delayed beta-adrenergic preconditioning with isoproterenol
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Group1
Group 2
Group 3
Group 4
24hrs 35 min RI 30 min Rep
I
t Control
I
tl-NA control
Ilh I I Itttt
4XO.0004 Iso i.p
Ilh I I _J_ I
I I I ,---.ttttt
l-NA (17.5mg/kg)
+4XO.0004 Iso i.p
t Administration of isoproterenol
i
t Administration of L-NA
Determination of infarct size by TIC staining
Fig.2.3 Experimental protocols for the role of NO in delayed ~ - adrenergic preconditioning
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Group 4: Pre-treatment with L-NA (Nw L-arginine) an hour before
pharmacological preconditioning with four repeated administrations of
isoproterenol ( 0.0004 mg/kg) an hour apart.
2.7.3 Determining the role of Reactive Oxygen Species in mediating 13-
adrenergic delayed preconditioning (Fig 2.4)
The free radical scavengers Melatonin, MPG and NAC was administered
before preconditioning with isoproterenol to investigate the role of ROS in
J3-adrenergicdelayed preconditioning.
Group 1 : No previous treatment.
Group 2: Treatment with 5 mg/kg melatonin alone
Group 3: Pre-treatment with melatonin (5 mg/kg) 5 minutes before
pharmacological preconditioning with four repeated injections of
isoproterenol (0.0004 mg/kg) an hour apart.
Group 4: Treatment with MPG (1 mg/kg) alone
Group 5: Administration of MPG (1 mg/kg) 5 minutes before
preconditioning with isoproterenol (four repeated injections of
isoproterenol 0.0004 mg/kg an hour apart).
Group 6: Administration NAC (10 mg/kg) alone before exposure to
ischaemia /reperfusion protocol.
Group 7: One injection of NAC (10 mg/kg) 5 minutes before
pharmacological preconditioning with four repeated injections of
isoproterenol (0.0004 mg/kg) an hour apart
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24hrs 35 min RI 30 min Rep
Group 1 /Control
Group 2 I /t 5mglkg Mel i.p
5min /Group 3 I I I I Ittttt
Mel (5 mg/kg) +Iso (4xO.0004i.p)
Group 4 I /t 1mg/kg MPG i.p
5min /Group 5 I I I I Ittttt
MPG(1mg/kg) +Iso (4xO.0004i.p)
(Protocols continued on next page)
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Group 6
Group 7
Group 8
24hrs 35 min RI 30 min Rep
I /u10mg/kg NAC .I.p i
15m1RI 1 1 1 /-~_____,.~----ril - I IUtttt
NAC(10mg/kg +lso(4xO.0004 i.p)
1''1 I I /tttt
---i
4xO.0004mg/kg Iso i.p
t Administration of isoproterenol t Administration of Mel t Administration ol MPG
U Administration of NAC
r Determination of infarct size by TIC staining
Fig.2.4 Free radical scavenger (Mel, MPG & NAC) pretreatment and J3- adrenergic delayed myocardial protection
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Group 8: Administration of 4 repeated injections of isoproteronol at
0.0004 mg/kg (an hour apart)
Investigating the protective effect of intraperitoneally
administrated melatonin (Fig 2.5)
(i) Effects of melatonin injected intraperitoneally on ischaemia!
reperfusion injury 24 hours later (Fig 2.5)
Group 1 : Control group no pretreatment.
Group 2 Pretreatment with 2.5mg/kg melatonin
intraperitoneally .
Group 3 : 5 mg/kg melatonin administered intraperitoneally.
(ii) Investigating the protective effect of orally administered
melatonin (Fig 2.6)
Melatonin was dissolved in ethanol and added to drinking water.
The final ethanol concentration (10,..d/100ml)was 0.01% for both
vehicle and melatonin treated rats. All rats received this
treatment for seven days. The water bottles were covered with
aluminium foil because melatonin is light sensitive and fresh
solutions were prepared daily for seven days.
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Group 1
Group 2
Group 3
24hrs 35 min RI 30 min Rep
t 2.5mgJkg Mel i.p
I
I
t 5mg/kg Mel i.p
t Administration of melatonin intraperitoneally
i Determination of infarct size by TTC staining
Fig.2.5 Experimental protocols for delayed preconditioning with intraperitoneal administration of melatonin
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7 days
Group1 I -:t Vehicle
Group 2 I /.
t Melatonin 20j.1g/ml
35 min RI 30 min Rep
Group 3
t Melatonin 40j.1g/ml
t Administration of melatonin orally
IDetermination of infarct size by TIC staining
Fig.2.6 Experimental protocols for melatonin supplementation in drinking water and effects on infarct size and functional recovery
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Experimental groups
Rats were randomly assigned to one of three groups
described below:
Group 1 : (Control group) Vehicle-ethanol (0.01%) that was
added to drinking water for seven days.
Group 2: Melatonin 20J.lg/ml drinking water for seven days.
Group 3: Melatonin 40 J.lg/ml drinking water for seven days.
(iii) Evaluation of the duration of the protective effect of oral
melatonin of following itswithdrawal (Fig 2.7)
Group 1: Control (0.01% ethanol) in drinking water.
Groups 2, 3, 4: All animals received melatonin 40 J.lg/ml in their
drinking water. Melatonin drinking water was replaced with normal
water for 2, 4 and 6 days respectively, after which the effect of
regional ischaemia was studied.
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7 days Withdrawal time 35 min RI 30 min Rep
Group 1 -:
I -:Group 2 t Melatonin 40J,lg/ml
I -:Group 3 t Melatonin 40J,lg/ml
I /Group4 t Melatonin 40J,lg/ml
t
i
Administration of melatonin orally
Determination of infarct size by TIC staining
Fig.2.7 Experimental protocols for effects of melatonin withdrawal on delayed myocardial preconditioning
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2.8 Biochemical analysis
2.8.1 Blood collection and plasma preparation
Rats were sacrificed after completion of the respective protocols.
Peripheral blood was collected into sterile vacutainer tubes containing
K3EOTA. Blood samples were centrifuged at 26X100g for 10 minutes at
4°C. The supernatant was removed and stored in sterile vacutainer tubes
at -20°C.
2.8.2 Melatonin assay principle
This assay procedure uses the basic principle of a radioimmunoassay.
The radioactive labeled melatonin and unbound melatonin (sample
melatonin) compete for a defined number of binding sites on the antibody.
The separation between antibody-bound and free tracer is accomplished
by the double antibody technique. The antibody-bound tracer is
precipitated with a second antibody in the presence of glycol. The
precipitate is counted in a gamma counter.
2.8.3 Melatonin assay procedure
Ten polystyrene tubes were labeled in duplicate. The first four polystyrene
tubes were labeled for total counts (TC) and Nonspecific binding (NSB).
The next fourteen tubes were labeled from A through to F (polystyrene
tubes coated with antibody to melatonin). The remaining four tubes were
controls (1,2) in duplicate. An additional forty tubes coated with anti-body
were labeled for samples, also in duplicate. A 100 ,.LI of standard A was
Stellenbosch University http://scholar.sun.ac.za
76
pipetted into tubes mark for NSB. Dispensed into the rest of the
polystyrene tubes were 100 JlIof standards A-F or 100 JlIof plasma/tissue
samples into respective tubes. To each tube was added 25 JlI of enzyme
solution except for TC. All tubes were vortexed briefly and centrifuged at
500 g for 1 minute. This was followed by incubation of all tubes at room
temperature for one hour. Then 50 JlI of assay buffer was added to every
tube which was followed by vortexing every tube. 50 JlIof 1-125tracer was
added to all tubes and all tubes were vortexed thoroughly. To each sample
50 JlI of diluted antiserum was added (except TC and NSB) and the
content of each tube was mixed. All tubes were incubated overnight (18-
20 hrs) at room temperature. A 500 JlIof cold (2-8 °C) precipitating reagent
was added to all tubes (except TC), this was followed by vortexing all
tubes thoroughly. An incubation period of 15 minutes at 2-8°C followed. All
samples were centrifuged at 3000 g for 15 minutes. The supernatant was
aspirated/decanted, and the radioactivity of the pellet counted for 60
seconds with a gamma counter.
2.9 Statistical procedure
All values were presented as mean ± standard error of the mean. One
way analysis of variance (ANOVA) combined with a Newman -Keuls post
hoc test was used to test for difference between groups. Infarct size was
expressed as a percentage of area at risk zone infarcted and an analysis
of covariance was performed to detect differences among groups.
Significant differences were defined as P< 0.05. All statistical procedures
were performed using PRISM software.
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Chapter 3
Results
3.1 Determination of optimal dose of isoproterenol that elicits f3 -
adrenergic Delayed Myocardial Preconditioning
3.1.1 The effect of isoproterenol pre-treatment on haemodynamic
parameters
3.1.1.1 Before sustained regional ischaemia ( Table 3.1 )
There was no significant difference in the basal heart rate, peak systolic
pressure, coronary flows, cardiac output, total work as measured amongst
all groups at 30 minutes of stabilisation. However, the aortic output of
group 5 was significantly lower in comparison with the control group
(* p<0.03)(Fig 3.1).
3.1.1.2 Haemodynamic parameters at reperfusion following sustained
regional ischaemia (Table 3.2)
Regional ischaemia of 35 minutes caused a significant reduction in all
parameters during reperfusion. Heart rate, peak systolic pressure,
coronary flow, aortic output, %functional recovery, cardiac output, and the
total work were not significantly different amongst all groups after
sustained regional ischaemia followed by 30 minutes of reperfusion.
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Table 3.1 : Haemodynamic function of isoproterenol treated hearts before regional ischaemia
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
n=17 n=6 n=9 n=5 n=7 n=7
HR (beats/min) 248.4±4.2 210.9±12.9 216.8±6.8 229.0±30.3 226.0±25.1 242.0±12.0
PSP(mmHg) 114.9±2.0 114.5±1.7 114.4±3.1 109.8±6.4 118.1±8.0 123.6±5.9
Coronary flow 17.1.±2.1 16.1±1.8 17.8±2.5 14.4±2.0 14.6±4.0 16.7±1.6
(ml/min)
Aortic output 36.9±O.6 34.3±O.9 34.1±O.9 32.6±2.6 28.3±3.1* 33.1±1.3
(ml/min)
Cardiac output 54.7±O.9 50.4±1.8 51.9±1.0 47.0±3.9 42.5±3.8 49.8±1.9
(ml/min)
Total work 14.2±O.4 12.9±O.4 13.4±O.5 11.6±1.1 11.6±1.3 10.3±O.9
(Watt)
. ----_.- ...-
All data presented as Mean ± SEM
P*<0.05 "vs" Group1
Abbreviations
Group 1 = Control
Group 2 = 2 x 0.04 mg/kg Isoproterenol
Group 3 = 1 x 0.04 mg/kg Isoproterenol
Group 4 = 2 x 0.02 mg/kg Isoproterenol
Group 5 = 4 x 0.004 mg/kg Isoproterenol
Group 6 = 4 x 0.0004 mg/kg Isoproterenol
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Table 3.2 : Haemodynamic functionof isoproterenol treated hearts after regional ischaemia
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
n=17 n=6 n=9 n=5 n=7 n=7
HR (beats/min) 244.1±18.8 222.9±6.1 219.2±28.3 235.0±19.7 187.5±34.1 251.7±11.2
PSP(mmHg) 87.8±5.5 92.5±2.1 78.7±9.9 88.9±3.4 80.5±13.4 95.9±2.1
Coronary flow 17.4±O.7 15.8±1.1 17.8±2.0 15.0±1.2 15.2±1.2 14.7±O.7
(ml/min)
Aortic output 15.6±O.7 18.4±2.7 10.6±2.0 12.3±2.7 10.9±2.1 14.6±1.7
(ml/min)
% Functional 45.8±2.4 54.0±3.6 35.1±5.2 38.7±9.1 41.5±4.6 43.3±4.3
recovery
Cardiac output 31.7±2.4 34.2±2.8 27.4±4.1 27.3±4.0 26.0±2.9 29.3±2.4
(ml/min)
Total work 6.7±O.5 7.2±O.6 5.4±O.8 5.5±O.9 5.0±O.9 6.4±O.6 !
(watt) !
All data presented as Mean ± SEM
P >0.05 "vs" Group1
Abbreviations
Group 1 = Control
Group 2 = 2 x 0.04 mg/kg Isoproterenol
Group 3 = 1 x 0.04 mg/kg Isoproterenol
Group 4 = 2 x 0.02 mg/kg Isoproterenol
Group 5 = 4 x 0.004 mg/kg Isoproterenol
Group 6 = 4 x 0.0004 mg/kg Isoproterenol
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3.1.2 The effect of isoproterenol pre-treatment on myocardial infarct size
3.1.2.1 Risk zone volume (Table 3.3)
Risk zone volume expressed as a percentage of left ventricle volume, was
the same in all groups, and were therefore comparable.
3.1.2.2 Infarct size (Fig 3.1)
Infarct size expressed as a percentage of area at risk (!IR) in the 6
experimental groups is presented in Fig (3.1). Infarct size of the control
animals was 38.9 ± 2.0%. All protocols of isoproterenol pre-treatment
except that of group 2 caused a significant decrease in infarct size.
Optimal protection was achieved at a dose of 4 xO.0004mg/kg - infarct size
was reduced by 70.9% in comparison to the controls. Therefore all further
interventions aimed at elucidating the mechanisms involved in f3 -
adrenergic delayed preconditioning utilised this protocol.
3.2 The role of eNOS in mediating f3 - adrenergic delayed myocardial
protection
To investigate whether beta adrenergic late preconditioning was mediated
via nitric oxide generation, an exogenous NOS inhibitor (L-NA) was
administered an hour before pharmacological preconditioning with four
repeated intraperitoneal injections of 0.0004mg/kg isoproterenol an hour
apart.
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Table 3.3: Isoproterenol pre-treated groups: Volume at risk expressed as a percentage of left ventricle volume
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 I
n=17 n=6 n=9 n=5 n=7 n=7
I
RIL 43.4%±2.3 48.4%±3.2 41.3%±4.5 36.6%±3.6 35.3%±4.6 40.4%±4.0
-----
,
R = Risk volume
L = Left ventricular volume
All data presented as Mean ± SEM
P>0.05 "vs" Group1
Abbreviations
Group 1 = Control
Group 2 = 2 x 0.04 mg/kg Isoproterenol
Group 3 = 1 x 0.04 mg/kg Isoproterenol
Group 4 = 2 x 0.02 mg/kg Isoproterenol
Group 5 = 4 x 0.004 mg/kg Isoproterenol
Group 6 = 4 x 0.0004 mg/kg Isoproterenol
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Fig. 3.1 The effect of Isoproterenol pre-treatment on infarct size
Groups
*p<O.05 vs Controls
Abbreviations
Iso = Isoproterenol
_Control
!±HE 2xO.04mglkg Iso
E31xO.04mglkg Iso
k ' I2xO.02mglkg Iso
~ 4xO.004mglkg Iso
_ 4xO.0004mglkg Iso
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3.2.1 Haemodynamic function before sustained regional ischaemia
(Table 3.4)
At the end of the stabilization period the cardiac output and coronary flow
of the L-NA + Isoproterenol pre-treated group (group 4) were significantly
reduced in comparison to the controls (Group1)(p<0.05). In group 2, that
was pre-treated with L-NA alone 24 hours before regional ischaemia, the
coronary flow and the peak systolic pressure were significantly lower than
controls (Group1). Heart rate, peak systolic pressure, aortic output, cardiac
output and total work were not significantly different amongst all other
groups.
3.2.2 Haemodynamic parameters at reperfusion following regional
ischaemia (Seetable 3 .5)
There was no significant difference in heart rate, peak systolic pressure,
aortic output (absolute or as a percentage of control value), total work, and
cardiac output after 30 minutes of reperfusion. The coronary flow of Group
4 remained significantly lower than the coronary flow of control group
(*p<0.02), but was not significantly different from other treated groups.
3.2.3 The effect of L-NA pre-treatment on infarct size
3.2.3.1 Risk zone (Table 3.6)
The left ventricular risk zone volumes were comparable in all four groups.
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Table 3.4 : Haemodynamic function of L-NA pre- treated hearts before regional ischaemia
Group 1 Group2 Group 3 Group 4
I
n=17 n=5 n=7 n=5
I
HR (beats/min) 248.4±4.2 227.0±6.7 242.0±12.0 218.3±16.4
I
PSP(mmHg) 114.9±2.0 97.0±0.6* 123.6±5.9 106.8±5.4
Coronary flow (ml/min) 17.1±2.1 12.9±0.8* 16.7±1.6 12.3±0.7*
.
i
Aortic output 36.9±0.6 34.4±1.3 33.1±1.3 34.0±2.0
(ml/min)
Cardiac output (ml/min) 54.7±0.9 47.3±1.2 49.8±1.9 46.9±2.5*
I
Total work 14.2±0.4 10.4±0.2 10.3±0.9 11.1±0.7
(Watt)
All data presented as Mean ± SEM
*P<0.05 "vs" Group1
Abbreviations
Group 1 = Control
Group2 = 17.5 mg/kg L-NA
Group 3= 4 x 0.0004 mg/kg Isoproterenol
Group 4= 17.5mg/kg L-NA + 4 X 0.0004mg/kg Isoproterenol
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Table 3.5: Haemodynamic function of L-NA pre- treated hearts at reperfusion following regional ischaemia
Group 1 Group 2 Group 3 Group 4
n=i7 n=5 n=7 n=5
HR (beats/min) 244.i±i8.8 224.0±2.3 25i.7±11.2 233.4±9.0
PSP(mmHg) 87.8±5.5 88.9±0.8 95.9±2.1 88.3±2.7
Coronary flow (ml/min) 17.4±0.7 15.1±1.9 14.7±0.7 13.4±i.6*
Aortic output(ml/min) 15.6±1.2 14.4±2.2 14.6±i.7 16.4±3.4
% Functional recovery 46.0±2.6 42.0±8.4 43.3±4.3 46.2±8.2
Cardiac output (ml/min) 31.7±2.4 29.5±1.1 29.3±2.4 29.8±3.8
Total work 6.7±0.5 5.9±0.2 6.4±0.6 6.2±0.7
(Watt)
All data presented as Mean ± SEM
P>0.05 "vs" Group l
Abbreviations
Group 1 = Control
Group 2 = i7.mg/kg L-NA
Group 3 = 4 x 0.0004 mg/kg Isoproterenol
Group 4= i7.5mg/kg L-NA + 4 X 0.0004mg/kg Isoproterenol
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Table 3.6: LNA -pretreated group: Volume at risk expressed as a percentage of left ventricle volume
Group 1 Group 2 Group 3 Group 4
n=17 n=5 n=7 n=5
R/L 43.1%±1.9 41.2%±3.7 40.4%±4.0 38.8%±3.8
R = Risk volume
L = Left ventricular volume
All data presented as Mean ± SEM
P>0.05 "vs" Group1
Abbreviations
Group 1 = Control
Group 2 = 17.5mg/kg L-NA
Group 3 = 4 x 0.0004 mg/kg Isoproterenol
Group 4' = 17.5mg/kg L-NA + 4 X 0.0004 mg/kg Isoproterenol
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3.2.3.2. Infarct size (Fig 3.2)
In the isoproterenol pre-treated group (group 3), infarct size was
significantly smaller in comparison to controls (Group1) (11.3±1.6% and
38.9±1.9% respectively). The group pre-treated with L-NA alone had an
infarct size that did not differ from the control treated group (31.4±3.8%
and 38.9±1.9% respectively). Treatment of hearts (Group 4) with
17.5mg/kg L-NA an hour before preconditioning with 4 repeated injections
of isoproterenol at dose O.0004mg/kg abrogated the infarct sparing effect
of pharmacological preconditioning with isoproterenol at dose
(4xO.0004mg/kg) 24 hours earlier.
These results suggest that NO generation during repeated f3 - stimulation
is necessary to trigger a delayed cardioprotective response.
3.3 Effects of free radical scavenger pre- treatment on delayed f3 -
adrenergic preconditioning
In order to investigate the role of ROS generation in f3 -adrenergic delayed
PC the following scavengers of ROS were used - Melatonin, MPG and
NAC.
3.3.1 The effect of ROS scavenger pre- treatment on delayed isoproterenol
preconditioning
Exogenous melatonin , MPG and NAC were administered in different
doses and time intervals before preconditioning with 4 intermittent
administrations of isoproterenol intraperitoneally and an hour apart, with
the aim to determine whether free radical scavengers pre-treatment before
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Fig 3.2 The effect of L-NA pre-treatment on infarct size
2
*
4
Groups
*p<O.05vs Group 1 and Group 3
3
Abbreviations
Iso = isoproterenol
L-NA = NtiJ-nitro-L-arginine
_Control
E317.5mg/kg L-NA
~ 4XO.0004mg/kg Iso
tmE 17.5mg/kg L-NA +
O.0004mg/kg Iso
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preconditioning with repeated l3-adrenergic stress would eliminate
protection afforded by this protocol.
Haemodynamic function before regional ischaemia
(Table 3.7)
Pretreatment with melatonin at dose 5mg/kg, MPG (1mg/kg) and NAC
(10mg/kg) did not have any effect on baseline parameters. However, in
isoproterenol pretreated group hearts (group 8) had a peak systolic
pressure that was significantly higher that group 1 and group 2.
Heart rate, coronary flow, cardiac output and total work measured at the
end of the stabilization period were not significantly different amongst all
groups (1-8) (Table 3.7).
3.3.1.2 Haemodynamic parameters at reperfusion following sustained
ischaemia (Table 3.8)
The heart rate, peak systolic pressure, coronary flow, aortic flow, cardiac
output, % functional recovery, and total work were similar in all groups.
3.3.2
3.3.2.1
The effect of ROS scavenger pretreatment on infarct size
Risk zone (Table 3.9)
The risk zones volumes expressed as a percentage of the left ventricle
were not significantly different from the normal control treated or vehicle
controls.
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Table 3.7 : Haemodynamic function of ROS scavenger treated hearts before regional ischaemia
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8
n=6 n=6 n=6 n=5 n=4 n=6 n=6 n=6
HR 249.0±13.5 240.0±7.4 243.0±6.7 264.0±19.9 250.0±3.6 261.0±4.9 262.0±15.1 242.0±12.0
(beats/min)
PSP(mmHg) 102.9±2.5 108.6±2.4 109.4±4.6 106.8±2.4 105.3±1.3 109.9±5.4 101.4±2.1 123.6±5.9*
Coronary 15.0±1.2 14.8±O.9 14.8±1.1 15.9±O.8 13.1±O.6 15.3±O.8 17.0±O.8 16.7±1.6
flow (ml/min)
Aortic output 41.6±2.4 39.0±3.2 31.7±1.1 39.2±1.7 40.0±O.7 42.8±1.2 39.8±1.7 33.1±1.3
(ml/min)
Cardiac 56.6±3.3 53.8±3.6 46.5±2.0 55.1±2.1 53.1±1.2 58.1±2.0 56.8±1.9 49.8±1.9
output
(ml/min)
Total work 13.3±1.0 13.8±O.9 11.6±O.8 13.5±O.7 14.0±O.6 14.5±O.7 13.1±O.7 10.3±O.9
(Watt)
-
All values presented as mean ± SEM *P<0.05 " vs" Group1
Group 1 = Control
Group 2 = 5mg/kg Melatonin
Group 3 = 5mg/kg Melatonin + 0.0004mg/kg Isoproterenol
Group 4 = 1mg/kg MPG
Group 5 = 1mg/kg MPG+4 x 0.0004 mg/kg Isoproterenol
Group 6 =1Omg/kg NAC
Group 7 = 10mg/kg NAC+4 x 0.0004 mg/kg Isoproterenol
Group 8 = 4 x 0.0004 mg/kg Isoproterenol
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Table 3.8 : Haemodynamic function of ROS scavenger treated hearts after regional ischaemia
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8
n=6 n=6 n=6 n=5 n=4 n=6 n=6 n=6
HR (beats/min) 256.0±19.3 244.0±8.9 254.0±15.4 240.0±10.4 227.0±23.7 240.0±3.9 258.0±12.4 251.7±11.2
PSP(mmHg) 88.3±2.4 92.6±1.65 96.0±2.4 95.4±1.3 96.1±2.9 92.4±1.0 94.9±3.5 95.9±2.1
Coronary flow 12.3±1.0 17.30±1.4 13.8±O.7 12.9±O.5 12.4±O.3 15.8±O.6 14.0±O.8 14.7±O.7
(ml/min)
Aortic output 16.8±2.2 19.7±2.5 18.2±1.5 22.4±1.3 19.0±2.9 21.5±1.9 15.5±2.4 14.6±71.7
(ml/min)
%Functional 46.0±2.6 47.7±4.7 57.4±5.2 57.9±5.4 47.4±8.3 50.0±4.0 39.9±6.6 43.3±4.3 ii
recovery
Cardiac output 29.1±2.5 36.9±3.6 31.7±1.2 38.8±2.7 31.4±2.6 37.3±2.2 29.5±2.7 29.3±2.4
(ml/min)
Total work 5.8±O.7 7.7±O.8 6.8±O.3 8.2±O.3 6.8±O.6 7.6±O.5 8.1±1.4 6.4±O.6
(Watt)
All values presented as mean ± SEM P>0.05 " vs" Group1
Group 1 = Control
Group 2 = 5mg/kg Melatonin
Group 3 = 5mg/kg Melatonin + 0.0004mg/kg Isoproterenol
Group 4 = 1mg/kg MPG
Group 5 = 1mg/kg MPG+4 x 0.0004 mg/kg Isoproterenol
Group 6 = 1Omg/kg NAC
Group 7 = 10mg/kg NAC+4 x 0.0004 mg/kg Isoproterenol
Group 8 = 4 x 0.0004 mg/kg Isoproterenol
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Table 3.9 : ROS scavenger pre-treated groups: Volume at risk expressed as a percentage of left ventricle volume
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8
n=6 n=6 n=6 n=5 n=4 n=6 n=6 n=6
40.9%±3.2 37.0%±4.1 33.5%±3.8 39.3%±4.8 45.9%±4.9 44.9%±4.7 44.4%±3.9 40.4%±4.0
RIL
---- _ .............. -------------- ~
R = Risk volume
L = Left ventricular volume
All data presented as Mean ± SEM
P>0.05 "vs" Group1
Abbreviations
Group 1 = Control
Group 2 = 5mg/kg Melatonin
Group 3 = 5mg/kg Melatonin + 0.0004mg/kg Isoproterenol
Group 4 = 1mg/kg MPG
Group 5 = 1mg/kg MPG+4 x 0.0004 mg/kg Isoproterenol
Group 6 =1Omg/kg NAC
Group 7 = 10mg/kg NAC+4 x 0.0004 mg/kg Isoproterenol
Group 8 = 4 x 0.0004 mg/kg Isoproterenol
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3.3.2.2 Effect of Melatonin on infarct size (Fig 3.3)
Melatonin administered at dose 5 mg/kg intraperitoneally, 24 hours before
regional ischaemia resulted in a highly significant decrease in infarct size
compared to the controls (9.5±1.3% and 36.9±2.3% respectively).
Pretreatment a with combination of melatonin (5mg/kg) + isoproterenol
(O.0004mg/kg) and isoproterenol (4XO.0004mg/kg) alone both resulted in
a highly significant decrease in infarct size (p<O.0001). These results
indicate that melatonin could not be used to study the effect of ROS
generation in isoproterenol induced delayed PC. Another important
deduction made from these results is the important role for melatonin as a
free radical scavenger that is so effective that it elicits a infarct sparing
effect 24 hours after pre- treatment. This observation led to an sub -study
that investigated the protective effect of i.p. and oral melatonin as reported
in section 3.4 and 3.5 of this thesis.
3.3.2.3 Effect of MPG on Infarct size (Fig3.3)
Pretreatment with combination of MPG(1mg/kg) + isoproterenol
(O.0004mg/kg) and MPG (1mg/kg) alone resulted in a significant reduction
in infarct size (p<O.0001). Similar to melatonin, our results of this protocol
and model indicated that MPG cannot be used to study the effect of ROS
generation in isoproterenol induced delayed PC.
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Fig 3.3 The effect of ROS scavenger pretreatment on infarct size
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3.3.2.4 Effect of NACon Infarct size (Fig 3.3)
Infarct sizes of Group1 did not differ from that of animals treated with 10
mg/kg NAG only on day 1 (Group 6). Values were 36.9 ±2.3% and 31.8 ±
2.8% respectively. Pre-treatment with 10 mg/kg NAG 5 minutes before
preconditioning with four repeated administrations of 0.0004mg/kg
isoproterenol Lp. abolished the delayed infarct sparing effect of repeated
isoproterenol stimulation - infarct size 36.9±2.3% for controls (group 1) and
35.9±2.8 for NAG + Iso combination group (group 7). These results
indicate that the mechanism of delayed 13- adrenergic myocardial
protection involves generation of reactive oxygen species.
3.4 Evaluation of melatonin as a protective agent
3.4.1 Intraperitoneal administration of melatonin
3.4.1.1 Haernodynamlc parameters before sustained regional ischaemia
(Table3.10)
Intraperitoneal melatonin treatment at doses 2.5 mg/kg and 5 mg/kg
significantly reduced pre-ischaemie coronary flows in comparison to the
control treated group. The coronary flows were 14.7 ±0.9 and 15.1 ± 0.5 in
group 2 and 3 respectively and 18.0 ± 0.70 in the controls (Group1). Peak
systolic pressure measured at the end of the stabilization period was
significantly higher in controls compared to both melatonin treated groups
(p<0.009). Heart rate, aortic output, cardiac output, and total work were
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Table 3.10 : Haemodynamic function of intraperitoneal melatonin treated hearts before regional ischaemia
Group 1 Group 2 Group 3
n=10 n=7 n=6
HR (beats/min) 245.0±7.1 250.7±5.4 240.1±8.1
PSP(mmHg) 118.6±2.7 103.1±1.7* 108.6±2.6* I
Coronary flow (ml/min) 18.0±O.7 14.7±O.9* 15.1±O.5*
Aortic output (ml/min) 36.9±O.6 45.1±O1.1 39.0±O3.2
I
Cardiac output (ml/min) 57.5±O.6 60.2±1.4 53.7±3.9
I
Total work 14.3±O.4 12.7±O.5 13.8±O.9
(Watt)
All data presented as Mean ± SEM
*P<O.05 "vs" Group1
Abbreviations
Group 1 = Control
Group 2 = 2.5mg/kg Melatonin
Group 3 = 5mg/kg Melatonin
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not affected by treatment with melatonin at both doses 24 hours earlier as
shown in table 3.10.
3.4.1.2 Haemodynamics after sustained regional ischaemia (Table 3.11)
There was no difference measured in heart rate, peak systolic pressure,
coronary flows, aortic flow, % functional recovery, cardiac output and total
work after 35 minutes of sustained regional ischaemia followed by 30
minutes of reperfusion.
3.4.1.3 The effect of intraperitoneal pretreatment on infarct size
3.4.1.3.1 Risk zone (Table 3.12)
The left ventricular risk zone was similar in all three groups.
3.4.1.3.2 Infarct size (Fig 3.4)
Pre - treatment with melatonin 5mg/kg or 2.5 mg/kg significantly reduced
infarct size expressed as a percentage of the risk zone when compared to
the infarct size of the control group (p<0.0001). In group 2 the infarct size
was reduced by 53.4% and in Group3 by 76.3% in comparison to the
control treated group (P<0.001). It is concluded that both melatonin doses
used afforded delayed cardioprotection.
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Table 3.11 : Haemodynamic function of intraperitoneal melatonin treated hearts after regional ischaemia
Group 1 Group 2 Group 3
n=10 n=7 n=6
HR (beats/min) 232.0±18.1 243.3±6.7 244.2±9.7
PSP(mmHg) 93.4±1.3 92.3±1.4 92.6±1.8
Coronary flow (ml/min) 17.1±1.1 13.5±1.0 17.2±1.5
Aortic output (ml/min) 15.6±O.7 20.3±O1.9 19.7±2.5
%Functional recovery 46.0±2.6 45.5±5.5 47.7±4.7
Cardiac output (ml/min) 33.1±2.1 33.7±2.3 36.9±4.0
Total work 6.7±O.5 7.0±O.5 7.7±O.8
(Watt)
All data presented as Mean ± SEM
P>O.05 "vs" Group1
Abbreviations
Group 1 = Control
Group 2 = 2.5mg/kg Melatonin
Group 3 = 5mg/kg Melatonin
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Table 3.12: Melatonin pre-treated intraperitoneally Volume at risk expressed as a percentage of left ventricle volume
Group 1 Group 2 Group 3 I
n=10 n=7 n=6
RIL 42.8%±1.8 46.9%±2.2 37.0%±4.1
I
R = Risk volume
L = Left ventricular volume
All data presented as Mean ± SEM
P>O.05 "vs" Group1
Abbreviations
Group 1 = Control
Group 2 = 2.5 mg/kg melatonin Lp.
Group 3 = 5mg/kg melatonin i.p.
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Fig 3.4 The effect of intraperttoneetly administration of Melatonin
on infarct size
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Effect of orally administrated doses of melatonin in drinking water
Before sustained regional ischaemia
Haemodynamics (Table 3.13)
Heart rate, peak systolic pressure, coronary flow, aortic output, cardiac
output and total work measured were similar in both 40f.lg/ml and 20f.lg/ml
pretreated groups as well as the vehicle (0.01 % ethanol) treated control
group. It is concluded that melatonin pre-treatment at doses 40f.lg/ml and
20f.lg/ml in drinking water for seven days as well as vehicle pretreatment
had no effect on haemodynamic parameters, before coronary artery
ligation.
3.5.2 Haemodynamics after sustained regional ischaemia (Table 3.14 )
The post ischaemie heart rates and coronary flow were not statistically
different amongs both orally pretreated groups as well as vehicle
pretreated group. Peak systolic pressure generation, aortic output, cardiac
output and % functional recovery in the high dose melatonin treated group
(40f.lg/ml) were significantly higher than in the vehicle treated control group
(p<0.05).
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Table 3.13 : Haemodynamic function of orally melatonin treated hearts before regional ischaemia
Group 1 Group 2 Group 3
n=9 n=7 n=8
HR (beats/min) 218.2±6.8 216.7±18.1 235.8±4.4
PSP(mmHg) 98.0±1.0 101.1±2.2 102.6±1.5
Coronary flow (ml/min) 13.9±O.7 12.6±O.6 14.0±O.7
Aortic output 38.2±O.7 38.9±1.4 39.8±1.3
(ml/min)
Cardiac output (ml/min) 52.1±1.4 51.5±2.1 53.8±1.9
Total work 12.0±O.5 11.9±O.4 12.7±O.5
(Watt)
All data presented as Mean ± SEM
P>O.05 "vs" Group1
Abbreviations
Group 1 = Control
Group 2 = 2mg/kg Melatonin
Group 3 = 4mg/kg Melatonin
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Table 3.14: Haemodynamic function of orally melatonin treated hearts after regional ischaemia
Group 1 Group 2 Group 3
n=9 n=7 n=8
HR (beats/min) 228.7±8.5 219.1±11.7 229.8±6.9
PSP(mmHg) 89.6±1.0 91.9±1.2 94.1 ±1.1.1 *
Coronary flow (ml/min 13.1±O.6 12.6±O.7 14.63±1.01
Aortic output (ml/min) 16.5±1.8 21.0±1.9 24.5±2.2*
%Functional recovery 43.2±4.8 53.8±4.4 62.0±5.5*
Cardiac output (ml/min) 29.6±2.1 33.6±2.5 39.1±1.4*
Total work 6.5±O.6 6.9±O.5 8.3±O.32
(Watt)
All data presented as Mean ± SEM
*P<O.05 "vs" Group1
Abbreviations
Group 1 = Control
Group 2 = 2mg/kg Melatonin
Group 3 = 4mg/kg Melatonin
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3.5.3 The effect of orally administrated melatonin on infarct size
3.5.3.1 Risk zone (Table 3.15)
Risk zones expressed as a percentage of the left ventricular volume, was
similar for all three groups.
3.5.3.2 Infarct size (Fig 3.5)
All rats drank 20- 25 ml per day and there was no difference in total daily
water consumption. The infarct areas for group 3, group 2 and group 1
(Fig 3.5) were 13.2±2.6, 35.4±4.0 and 35.1±4.1, respectively. Rats
receiving low dose melatonin (20J.!g/ml)(Group 2) for seven days had an
infarct size similar to control treated rats that were treated with vehicle
(0.01% etOH). High dose melatonin (40J.!g/ml)(Group 3) administration for
seven days before exposure to sustained regional ischaemia 24 hours
later (Group3)(p<0.0003) resulted in a 62.04% reduction in infarct size in
comparison to the vehicle - treated rats.
3.6 The effect of melatonin withdrawal on infarct size (Fig 3.6)
When melatonin was administered in drinking water for 7 days, withdrawal
of two days resulted in no loss of protection, as infarct size in this group
was similar to the group sacrificed on day O. Withdrawal of melatonin for
up to 4 days resulted in an increase of infarct size (26.0±4.6%) and
protection was totally lost after 6 days withdrawal (37.8±3.9%). These
results demonstrate that melatonin administered in this mode and
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Table 3.15: Melatonin pre-treated orally : Volume at risk expressed as a percentage of left ventricle volume
Group 1 Group 2 Group 3
n=9 n=7 n=8
RIL 46.6%±1.1 40.2%±4.5 40.3%±3.8
R = Risk volume
L = Left ventricular volume
All data presented as Mean ± SEM
P >0.05 "vs" Group1
Abbreviations
Group 1 = Control
Group 2 = 2mg/kg Melatonin
Group 3 = 4mg/kg Melatonin
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Fig 3.5 The effect of orally supplemented melatonin on infarct size
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Fig. 3.6 The effect of melatonin withdrawal on infarct size
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protocols resulted in significant myocardial protection against infarction for
up to 48 hours later.
3.7 Biochemical results
3.7.1 Serum melatonin levels (Fig 3.7)
The melatonin assay only allows a certain amount of samples and
therefore only selected samples were done in triplicate. The serum
melatonin level of both pretreated groups (2.5 mg/kg and 5 mg/kg) was
122.4 pg/ml and 160.0 pg/ml respectively. Although the serum melatonin
values were higher than those of the control treated hearts (86.6pg/ml) the
difference was not significant. Serum melatonin levels of group 4 and
group 5 (melatonin withdrawal groups) did not differ from control serum
values.
Stellenbosch University http://scholar.sun.ac.za
e 400
o
~-e
(1)_u-c: Eo-uel
c:'::
eon; 100
Q;
:i!:
Fig 3.7 The effect of melatonin treatment on serum values
6
Groups
p>O.05vs Controls
~Controls
E:3 5mg/kg Mel i.p
8±E32.5mg/kg Mel i.p
~ 4days withdrawal
_ 6days withdrawal
Stellenbosch University http://scholar.sun.ac.za
88
CHAPTER4
Discussion
4.1 Introduction
Myocardial protection against the consequences of ischaemia is an
important goal to pursue, as many patients are exposed to myocardial
ischaemia daily. For this reason exogenous and endogenous agents have
been studied over the past decades. One problem that always limited the
clinical usefulness of studies on myocardial protection was the fact that
protective agents had to be administered in the acute setting, i.e.
immediately prior to the occurrence of ischaemia, or during reperfusion.
The phenomenon of preconditioning opened a new horizon in the quest for
protection of the myocardium. Firstly it was regarded as the most potent
form of myocardial protection against ischaemia yet observed. Secondly,
the "second window of protection" of preconditioning with ischaemia made
it possible to activate the protective mechanism against ischaemia long
before ischaemia occurred.
In this study it was attempted to investigate whether SWOP could be
activated pharmacologically with beta- adrenergic stimulation, and to
elucidate the mechanism of this protection. Furthermore, in a sub-study,
the ability of an endogenous agent, melatonin (an endogenous substance
produced by the pineal gland), to confer longterm protection against
ischaemia was studied. The specific aims of this sub-study was to
investigate the effectiveness of systemically and orally administered
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melatonin to protect against infarct size, and to investigate the duration of
protection conferred by oral administration.
The major findings of this study can be summarised as follows:
1. In vivo treatment with isoproterenol elicited a dose dependent infarct
limiting effect against 35 minutes of regional ischaemia. The optimal
protection was achieved with four repeated intraperitoneal injections at
dose O.0004mg/kg and the infarct size was reduced by 71% in comparison
to the control group.
2. This ~-adrenergic delayed myocardial protection is NO mediated, as the
non- selective NOS inhibitor (L-NA) administered an hour before
preconditioning with isoproterenol (4 X O.0004mg/kg) abolished the
protection elicited with repeated ~ - adrenergic stimulation.
3. This ~-adrenergic delayed myocardial protection is also mediated by
the generation of reactive oxygen species, as NAC, a ROS scavenger,
administered 5 minutes before eliciting delayed preconditioning with
isoproterenol (4 X O.0004mg/kg) completely abrogated the infarct sparing
effect.
4. Intraperitoneally and orally administered melatonin both protected
against 35 minutes of sustained regional ischaemia induced 24 hours after
administration of the drug. The protective effect of orally administered
melatonin continued 48h after cessation of oral treatment. Serum levels of
melatonin did not correlate with cardiac protection against ischaemia.
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4.2 Appropriateness of the end-points - infarct size and functional
recovery
There has been a longstanding difference of opinion concerning the best
end-point to use to assess myocardial protection - infarct size or functional
recovery. The main reason for the disagreement was that a smaller infarct
size was not necessarily associated with improved recovery (Cohen et al.,
1999), thus generating conflicting interpretations about the validity and
meaning of the results obtained with either end-point. For this reason we
have systematically evaluated the role of the perfusion model (retrograde
vs working), the infarct size and severity of ischaemia (regional vs global)
as well as the endpoint (functional recovery vs infarct size) in
preconditioning (Lochner et al., 2003). In that study, the isolated perfused
rat heart was preconditioned by 3 x 5 min global ischaemia, followed by
different periods of regional or global ischaemia and reperfusion.
Ischaemic preconditioning of working hearts resulted in increased
functional recovery (i.e. aorta flow and cardiac output) after 25-35 min
global ischaemia, while retrogradely perfused hearts showed no significant
improvement (i.e. developed pressure), except after 30 min global
ischaemia. In addition, the percentage reduction in functional performance
during reperfusion observed in the latter group was significantly less than
in working hearts. Of more relevance to the work presented in this thesis
are the findings with regard to hearts subjected to regional ischaemia.
Hearts were perfused in either retrograde or working mode followed by
infarct size determination. Regionally ischaemic working as well as
retrogradely perfused hearts when preconditioned showed a significant
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increase in functional recovery after 35 min ischaemia only. In contrast to
global ischaemia, the percentage recovery in mechanical performance of
regionally ischaemic hearts was not affected by the mode of perfusion.
Preconditioning of working hearts caused a significant reduction in infarct
size after both 30 and 35 min ischaemia. However, preconditioned
retrogradely perfused hearts showed a significant decline in infarct size
after 35 min regional ischaemia only. In conclusion, the effect of the
perfusion mode on functional recovery was dependent on the size and
severity of ischaemia. It also affected the ischaemie time at which infarct
size reduction by prior preconditioning occurred in the retrogradely
perfused heart.
It can thus be confidently stated that the endpoints used in this study were
well validated, and relevant. In our study, animals were treated
pharmacologically (in vivo) 24h prior to inflicting the infarct on excised
hearts and infarct size was determined on hearts from this in vitro study.
The next question is therefore whether there are differences in infarct size
in in vivo and in vitro studies. In studies of delayed preconditioning, both in
vivo and in vitro (isolated buffer perfused hearts) studies showed a similar
reduction in infarct size. Studies in the dog (Kuzuya et al., 1993) and rabbit
(Marber et al., 1993) observed delayed preconditioning against infarct size
in vivo, that were similar to the reduction in infarct size observed in in vitro
studies, such as in rats (Yamashita et al., 1998) and in mice (Zhao et al.,
2000). Based on previous studies done at our laboratory we decided to
ignore a reperfusion priod longer than 30 minutes. Results from these
studies indicated that hearts exposed to the same perfusion protocol and
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stained with triphenyl tetrazouurn irrespective of reperfusion periods, 30
and 120 minutes, did not have different infarct sizes. Preference is given to
the shorter reperfusion period as the longer reperfusion period is known to
suppress cardiac function (unpublished observations).
4.3 J3 . stimulation with isoproterenol elicits dayed cardioprotection
The first aim of the study was to investigate whether J3-stimulationwith
isoproterenol could elicit delayed protection. A dose finding study was
undertaken, and different doses of isoproterenol at different repeated
intervals were administered to animals. Baseline functional characteristics
of hearts were similar for all groups with the exception of Group 5, which
had a significantly lower aorta output than the other groups. No
explanation for this could be discerned, as the ability of this group to
generate pressure was in the high range compared to the other groups.
The area at risk for infarction was comparable between all groups.
Preconditioning with isoproterenol successfully elicited delayed myocardial
protection as determined by measuring infarct size, and the ability to
induce protection increased with a decrease in isoproterenol dose and
increase in the number of administrations. Hearts preconditioned with
isoproterenol 0.04mg/kg or two administrations of isoproterenol 0.04mg/kg
three hours apart were least effective. The most effective preconditioning
protocol was the administration of isoproterenol at a dose of
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(4X 0.0004mg/kg), one hour apart which resulted in a 71% reduction in
infarct size compared to controls.
It is important to notice that the isoproterenol dose found to elicit delayed
preconditioning was a very low dose. In a previous study from this
laboratory (Marais et aI., 2001), it was also found that classic
preconditioning was elicited by a very low dose of isoproterenol - 10-7 M.
Indeed, we found at that time that 10-8 M was equally effective.
Furthermore, it was the single administration of isoproterenol 10-7 M that
elicited classic preconditioning - repeated administrations of isoproterenol
(5 minutes apart) failed to elicit protection (unpublished observations). It
therefore seems as if there is a fine line of distinction between beneficial
and detrimental effects of beta-adrenergic stimulation. The observations in
this thesis were very similar - the most effective protocol was observed
with the lowest dose, repeated at hourly intervals.
In this study isoproterenol elicited delayed protection did not cause an
improvement in mechanical function of the hearts that showed a significant
reduction in infarct size after the regional ischaemie period. The study from
our laboratory discussed above (validity of end-point (section 4.2)) concurs
with this observation - when regional ischaemia is used, the duration of
ischaemia has to exceed 35 minutes before an effect on functional
recovery is observed. It must however be noted that in similar studies by
Ping et al., (1999), Takano et al., (1998 a), Takano et al., (1998) and Xuan
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et al., (1994) it was shown that late PC not only reduced infarct size but
also produced a modest improvement of left ventricular systolic wall
thickening during the first few days after 30 minutes of coronary occlusion.
These experiments were all done in vivo, and this may play an important
role due to the presence of other hormonal factors that may contribute to
functional recovery of the hearts. Another explanation may be the timing
post-infarction. In a study on delayed preconditioning with ischaemia as
the preconditioning trigger, Takano et al (2000) reported enhanced left
ventricular function in rabbits subjected to 30 minutes of coronary artery
occlusion followed by 28 days of reperfusion. It is possible that we did not
observe improved contractile function due to a too short reperfusion period
(30 minutes) - myocardial stunning is known to persist for weeks after
reperfusion ( Bush et al., 1983, Lavalee et al., 1983). As will be discussed
below, the ROS scavenger melatonin was able to reduce infarct size and
improve functional recovery in heart exposed to identical circumstances of
regional ischaemia. This invokes the possibility that isoproterenol does not
change the way in which the myocardium handles ROS, and that
protecting mechanisms against infarction are distinct from protection
against functional recovery. In conclusion, due to the short reperfusion
period studied in an in vitro system, it is not possible to make any
meaningful deductions about the ability of isoproterenol elicited delayed
preconditioning to improve functional recovery.
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This is the first study to demonstrate that in vivo treatment with
isoproterenol elicits delayed preconditioning. The finding is exciting, as it
implies that this mode of eliciting myocardial protection should be
investigated in the clinical setting. A potential group of patients who may
benefit from this approach may be those who undergo open heart surgery,
and have to go on bypass. Another group who will have to be looked at
again is patients with severe intractable heart failure. This latter group of
patients is often treated with infusions of dobutamine for periods of 48 - 72
hours. Dobutamine, which has beta-adrenergic actions, has also been
shown to elicit classic preconditioning (Asimakis & Conti, 1995).
Dobutamine infusion clearly improves symptoms in these patients, but also
shortens their survival (Dies et al., 1986). It is clear from our study that
high doses of isoproterenol did not elicit protection - indeed, the starting
dose (0.04mg/kg) was obtained from a study by Woodiwiss et al. (2001) in
which daily administration of isoproterenol in that dose was used to induce
cardiomyopathy! The question that arises is: will the molecular changes
induced by isoproterenol as shown above be beneficial to patients with
heart failure or is it due to a specific protection against ischaemia? Further
can low dose isoproterenol or dobutamine infusions improve symptoms in
patients with intractable heart failure without having a deleterious effect on
their survival.
The finding that beta-adrenergic stimulation elicits delayed preconditioning
is novel and exciting, but should not come as a surprise. All agents shown
to elicit classic preconditioning were able to elicit delayed preconditioning.
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As explained in detail in the literature review, the ability of isoproterenol to
elicit classic preconditioning was known, and it was therefore reasonable
to expect it to elicit delayed preconditioning too. A delayed protective
effect of transient beta-adrenergic stimulation is also known, albeit not
typical delayed preconditioning. Meng et aI., (1993) demonstrated that the
administration of noradrenaline 24 hours, but not 4 hours earlier prior to
ischaemia, resulted in enhanced contractile function. Beckman and
colleagues (1981) observed that dogs that developed long term tolerance
to intravenously administered adrenaline were also resistant to the
ischaemic effects of coronary embolization with micropheres. In this study
1 of 14 tolerant dogs fibrillated on coronary artery occlusion compared with
11 of 32 in the control treated group. Kovanecz and co-workers (1996)
reported that intravenous administrations of isoproterenol induced
longterm cardiac adaptation 24 to 48 hours after preconditioning using
electrocardiographic changes as end-point. In this study isoproterenol was
administered intravenously at dose (5X2j.!g/kg at ten minute intervals) in
rabbits and resulted a reduced stress induced elevation in the ST segment
of endocardial EGG 6, 24 and 48 hours later.
4.4 The role of nitric oxide in f3 • adrenergic delayed preconditioning
L-NA, a nonselective inhibitor of all three NOS isoforms (Southan and
Szabó 1996) was used to investigate whether beta-adrenergic delayed
preconditioning was mediated by nitric oxide production. L-NA was
administered an hour before preconditioning hearts with four repeated
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doses of isoproterenol O.0004mg/kg, an hour apart. Significant drug
effects were observed in the L-NA treated groups - L-NA caused a
significant decrease in coronary flow in both the groups treated with L-NA
alone, and in the group preconditioned with isoproterenol. This reflects the
importance of NO in coronary flow regulation, which is distinct from the
role played by adenosine (Suarez & Torres, 1998). However, this drug
effect had no significant effect on the ability of hearts to generate
pressure, and had no effect on the area at risk for infarction.
L-NA pre-treatment abolished the infarct limiting effect of delayed beta-
adrenergic preconditioning completely. The drug effect of L-NA (a
decrease in coronary artery flow) was not the reason for this observation,
as the control group treated with L-NA alone had a similar (and not larger)
infarct size as the untreated control group. This observation indicates that
the protective mechanism of delayed isoproterenol induced
preconditioning is nitric oxide mediated.
This finding is in agreement with the "NO hypothesis of delayed
preconditioning" as advanced by Bolli and co-workers (1997). They
postulated that NO acts as both trigger and distal mediator of delayed
myocardial protection. Delayed myocardial preconditioning against
myocardial stunning and infarction was abolished by treatment with a NOS
inhibitor during the preconditioning phase in rabbits (Bolli et al., 1997 , Qui
et al., 1997). The role of NO as a trigger is further supported by
observations that pre-treatment with the NO donors diethylenetriamine-NO
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and S-nitroso-N-pencillamine induced protection against both myocardial
stunning and infarction 24 hours later (Qui et aL1997a, Shinmura et al.
1997).
We hypothesize that NO generated as a result of beta-adrenergic receptor
activation stimulates myocardial adaptation through a cascade of
intracellular events similar to those evoked for second window of
ischaemie preconditioning (Bolli et aL,1997). The mechanism by which
isoproterenol mediated delayed preconditioning involves NO has to be
addressed. It is known that endothelial NOS is activated upon beta-
adrenergic stimulation (Balligand et al., 1999), and this is therefore the
most likely explanation for our results. Endothelial NOS (eNOS) is the
most represented constitutive form of NO synthase in the ventricular
myocardium. The fact that L-NA abrogated the infarct limiting effect of
isoproterenol (l3-adrenergic) delayed preconditioning could implicate that
the mechanism of cardioprotection could involve eNOS. Balligand et al
(1993) reported an increased contractile response of ventricular myocytes
to isoproterenol in the presence of NOS inhibitor N-N Arg which supports a
functional regulatory role of NO on contractility. However, we have not
shown endothelial NOS activation, and conclusions concerning the
connection between isoproterenol administration and eNOS activation are
speculative at this stage. Furthermore, our results do not enable one to
identify which isoform(s) is involved, as L-NA is a non-selective inhibitor of
all the isoforms of NOS. Thus, the precise isoform that is involved in the
Stellenbosch University http://scholar.sun.ac.za
99
development of delayed isoproterenol induced myocardial adaption is still
not clear.
Delayed PC is not affected by pre-treatment with the guanylate cyclase
inhibitor 000 (Kodani 2000a) but is completely abolished by pre-treatment
with the antioxidant mercaptopropionyl glycine (Takano et al., 1998, Tang
et aI., 1997). In view of this, it has been postulated that nitric oxide
generates peroxynitrate which then protonates and decomposes to
generate the hydroxy radical or some other potent radical similar in activity
(Kodani et aI., 2002, Beckman et aI., 1990). It thus suggests that the
generation of ROS is important in the mechanism of delayed
preconditioning. In our experiments, the effect of 000 on isoproterenol
induced delayed preconditioning was not investigated. Our results can
therefore be criticised as not being able to exclude a role for cGMP in the
mechanism of protection. In view of the above findings however, it is highly
unlikely that 000 would abolish isoproterenol induced delayed
preconditioning.
One can speculate on the sub cellular mechanisms involved in eliciting
delayed protection with isoproterenol. The sub cellular mechanisms of
action of isoproterenol have been established. The stimulation of the beta-
adrenergic receptor (for example by isoproterenol) couple to G-stimulatory
proteins to stimulate the production of cAMP through activation of
adenylate cyclase (Fleming et aI., 1992). PKA is activated via cAMP and
stimulates the L-type voltage channels (Schroder & Herzig, 1999 ) by
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phosphorylation. In our study different protocols and doses employed
resulted in a reduction in infarction 24 hours later. In would be reasonable
to speculate that in these protocols a threshold of cAMP was reached to
trigger changes that resulted in delayed myocardial protection. On the
other hand, it seems as if beta-adrenergic stimulation was not excessive,
and avoided excessive cAMP increases and their accompanying toxic
side-effects. Further biochemical studies to determine the exact level of
cAMP needed to trigger this delayed cardioprotective response are
needed.
Another possibility is that PKC activation was responsible for activating the
protection. Work done by Miyawaki and Ashraf (1997) demonstrated
specific PKC inhibitors abolished isoproterenol induced cardioprotection.
Evidence for the earliest involvement of PKC in delayed preconditioning
was reported by Yamashita et al.(1994) who showed that staurosporine, a
PKC inhibitor, prevented delayed preconditioning in myocytes
preconditioned with hypoxia. To date the exact mechanism through which
PKC results in delayed myocardial preconditioning is not very clear. It has
been proposed that PKC could influence many transcription events either
by directly phosphorylating transcription factors or indirectly via activation
of MAP kinase families (Hug & Sarre, 1993). The involvement of PKC in
isoproterenol induced delayed preconditioning was not studied in this
thesis.
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4.5 The role of oxygen radicals in mediating delayed 13 preconditioning
Oxygen radicals produced in the setting of ischaemic preconditioning
contribute to delayed myocardial adaptation (Sun et aI., 1996). Beta-
adrenergic stimulation also produces free radicals (Opie et aI., 1979). To
investigate the role of free radicals in our model we utilised three free
radical scavengers namely melatonin, mercapto-propionyl glycine and N-
acetylcysteine. Animals were pretreated with 5 mg/kg melatonin, MPG
(1mg/kg) or N-acetylcysteine 10mg/kg intraperitoneally half an hour before
preconditioning with four repeated injections of isoproterenol at dose
O.0004mg/kg an hour apart. None of these drugs had any effect on
haemodynamic parameters before induction of regional ischaemia, or on
area at risk for infarction. Only N-acetylcysteine abolished the infarct
sparing effect of isoproterenol induced delayed preconditioning. The
reason for this becomes apparent when one studies the effect of the two
other ROS scavengers, melatonin and MPG, on control hearts. From the
data it is clear that both these ROS scavengers have an inherent and
long-lasting protective effect against myocardial ischaemia, as infarct size
was reduced to a similar extent as hearts preconditioned with
isoproterenol alone. These results are similar to the findings of Bell and
workers (1999), who pretreated hearts with MPG (300l-lmol/l) before
treating with a SNAP donor (2I-lmol/l) to elicit myocardial protection. The
protection afforded by the SNAP donor was also not abolished by MPG in
these experiments.
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Chen et al (1995) also reported that classic ischaemic preconditioning is
associated with a more oxidized cellular redox state, and the
administration of N-acetylcysteine, a glutathione precursor during
preconditioning blocked the protective effects of preconditioning. The
production of free radicals during ischaemic preconditioning is also
involved in the mechanism against myocardial stunning in conscious pigs
(Sun et al., 1996).
These results thus confirm that isoproterenol induced delayed
preconditioning is also dependent on the generation of ROS, similar to the
findings in hearts preconditioned with ischaemia (Takano et al., 1998a,
Tang et al., 1997a). It also provides indirect support for the hypothesis that
the generation of nitric oxide generates peroxynitrate which somehow
induces protection. It is also clear that melatonin and MPG cannot be used
to study the effect of ROS in the experimental setting, due to their strongly
protective effects. This provided the basis to study one of these drugs,
melatonin, in more depth.
4.6 The protective effect of melatonin against ischaemia
In view of the observed effects of melatonin described above, the systemic
(intraperitoneal) as well as oral administration of melatonin was
investigated in more detail. Haemodynamic parameters at baseline were
similar for the different groups treated with intraperitoneal melatonin, with
the exception of coronary flow, which was less in melatonin treated
groups. An effect of melatonin on coronary circulation has not been
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described elsewhere. Also, in Table 3.7, no such effect of any of the other
ROS scavengers, was noted, which argues against a general propensity
for ROS scavengers to reduce coronary flow. In Table 3.13 no such effect
for oral melatonin was documented. This observation remains difficult to
explain. However, there was no significant difference in the infarct zone at
risk in these hearts.
Intraperitoneal melatonin administration had a pronounced protective
effect against an ischaemie insult given 24 h later, both in hearts treated
with intraperitoneal and oral melatonin. When melatonin was adminstered
intraperitoneally, both doses (2.5 mg/kg and 5 mg/kg) reduced infarct size
(Fig 3.4) significantly in comparison to the control treated hearts. Others
have demonstrated a protective action of melatonin against ischaemia, but
in all these experiments the ischaemia was studied in an acute setting. For
instance, Lagneux et al (2000) showed that hearts pretreated with
melatonin (1 or 10mg/kg i.p.) and the analogue 5-MCA-NAT (10mg/kg
i.p.) thirty minutes before hearts were exposed to regional ischaemia (30
minutes) provided effective protection against infarction. Similarly, in an in
vivo study by Lee et al. (2002) a bolus intravenous injection of 0.5 , 1.0
and 5.0 mg/kg melatonin before LAD occlusion protected against
ischaemia/reperfusion tachycardia and fibrillation. The results shown
above (Figures 3.4, 3.5) are the first to prove that the protective effect of
melatonin extended beyond the acute time frame, and was observed 24
hours after administration.
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The observation that systemic administration of melatonin had a long
lasting protective effect against ischaemia prompted the question whether
oral administration shared this property. Our work demonstrated that
melatonin administration of 40)lg/ml (but not 20 )lg/ml) in the drinking
water for seven days protected against infarction 24 hours later (Fig 3.5).
Furthermore, the haemodynamic parameters (PSP, CO and aortic output
post ischaemia) of the high dose melatonin treated group were
significantly higher than low dose treated group and vehicle treated
controls (Table 3.15). These findings are very significant, as it suggests
the possibility that it may be worthwhile to investigate the possibility of
using oral melatonin administration to protect against myocardial
ischaemia in other species, including humans. A novel finding is that oral
melatonin not only protected against infarct size, but also improved
functional recovery. As pointed out above, protection against functional
recovery was not observed with isoproterenol induced delayed
preconditioning. These findings support the idea that ROS generation may
play an important role in the pathophysiology of stunning, as has been
discussed by Opie (1997). It must however be stated that the issue of free
radicals and infarction is not without controversy (Jeroudi et al., 1994), but
our results support a role for free radicals in both infarction and stunning. It
also suggests that the protective effects against infarction and stunning
are distinct - isoproterenol induced delayed protection can activate the
anti-infarct protection, but does not seem to be able to protect against
stunning. Melatonin seems to be able to protect both against ischaemia
and stunning.
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The question arises why oral administration of melatonin, but not
intraperitoneal melatonin, was accompanied by improved functional
recovery. A critical appraisal of the data in Table 3.10 and 3.13 suggest
that the answer may lie in the fact that the groups of animal studied during
the oral administration were more homogenous in their pre-ischaemia
haemodynamic characteristics than was the case in the experiments
where melatonin was administered intraperitoneally. It is highly unlikely
that melatonin would affect the coronary flow of intraperitoneally treated
animals differently than when administered orally. Also, no effect of
melatonin on coronary flow has been documented to date.
Once it was established that oral administration of melatonin in a dose of
40I-ig/mI provided protection against myocardial ischaemia, the question
was asked how long this protective effect lasted. From our experiments it
is clear that the effect was still strongly present 48 hours after cessation of
oral intake, virtually lost at 72 hours and totally lost at 96 hours. The time
course of loss of protection of oral melatonin has not been described
previously.
The question that arises from these observations is whether serum or
myocardial tissue levels of melatonin had any relationship to protection.
Serum levels of melatonin from selected experimental conditions in which
there was a wide variation of infarct protecting effects were therefore
measured. Serum melatonin levels had no relationship to protection by
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melatonin, which may indicate that it is not of any importance, or that
tissue levels are more important. This aspect will have to be studied in
future.
4.7 Mechanism of action of melatonin
Ischaemia and reperfusion is associated with rapid reoxygenation of
ischaemic tissues and is associated with the generation of highly reactive
oxygen species. The efficacy of melatonin to protect against ischaemia is
most likely due to its actions as a scavenger of radical oxygen species.
The high lipid solubility of melatonin allows this substance to readily enter
the cytosol and cellular compartments where it can act as an endogenous
antioxidant and a scavenger of toxic free radicals (Hardeland & Rodrigues,
1995). Further proof of the anti-oxidant action of melatonin comes from
observations in our laboratory. Isolated adult rat ventricular myocytes
were pretreated with 50 and 100 IlM melatonin before being subjected to
12.5 min chemical hypoxia. Pretreated cardiomyocytes showed marked
morphological improvement, and reduced fluorescence intensity of
DCDHF, DHR and Fluo which indicates that melatonin effectively reduced
damage induced by chemical hypoxia. The activity of melatonin in vitro
has been shown to be superior to that of glutathione (Tan et al., 1993) and
of Vitamin E (Pieri et al., 1994). Also, melatonin is able to stimulate
antioxidative enzymes, such as glutathione peroxydase and superoxide
dismutase (Reiter et al., 1997, Kotler et al., 1998). Melatonin also binds to
nuclear binding sites (Kotler et aI., 1998). Chen et al (1994) have
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demonstrated that melatonin pretreatment protected against adriamycin
induced cardiomyopathy, another pathology involving toxic free radicals.
In addition to melatonin, other methoxyindoles may have therapeutic
properties - for instance, 5 - methoxytryptamine also has a radioprotective
action (Lebkova, 1966 , Feher et al., 1968 , Hara et et al., 1997). 5 -
methoxytryptamine and other methoxyindoles are present in the serum,
pineal gland and retina of animals (Tsang et al., 1996 , Li et al., 1997a , Li
et al., 1997b , Zawilska et al., 1998 , Vivien et al., 1999) - all of these are
currently being investigated for their therapeutic effects. The fact that 5 -
methoxyindols are potent antioxidants and that melatonin is a relatively
safe molecule (Bubenik et al., 1998) with clinical potential justify further
examination of its use in animal models and human studies.
4.8 Conclusion
The present study advances our understanding of the mechanism of
delayed myocardial preconditioning. Our results support a role for beta-
adrenergic stimulation with isoproterenol as a trigger of delayed
preconditioning. The optimal dose that successfully elicits delayed
preconditioning in the rat was 4xO.0004mg/kg given one hour apart.
Reduction in infarct size in isoproterenol induced delayed protection is not
associated with improvement in functional recovery. Beta-adrenergic
delayed preconditioning is mediated through nitric oxide (NOS) activation
as well as the generation of reactive oxygen species. Melatonin protects
against regional ischaemia and results in reduced infarct size when
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administered orally and intraperitoneally and also in improved functional
recovery (when administered orally). These findings provide evidence that
both these therapeutic strategies are potentially useful in protecting
patients against myocardial ischaemia.
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